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Abstract
Substantial progress has been made in human genetics and genomics research over the past ten years since the
publication of the draft sequence of the human genome in 2001. Findings emanating directly from the Human
Genome Project, together with those from follow-on studies, have had an enormous impact on our understand-
ing of the architecture and function of the human genome. Major developments have been made in cataloguing
genetic variation, the International HapMap Project, and with respect to advances in genotyping technologies.
These developments are vital for the emergence of genome-wide association studies in the investigation of
complex diseases and traits. In parallel, the advent of high-throughput sequencing technologies has ushered in the
‘personal genome sequencing’ era for both normal and cancer genomes, and made possible large-scale genome
sequencing studies such as the 1000 Genomes Project and the International Cancer Genome Consortium. The
high-throughput sequencing and sequence-capture technologies are also providing new opportunities to study
Mendelian disorders through exome sequencing and whole-genome sequencing. This paper reviews these major
developments in human genetics and genomics over the past decade.
Keywords: Human Genome Project, International HapMap Project, 1000 Genomes Project, genome-wide association
studies, single nucleotide polymorphisms, copy number variations, next-generation sequencing technologies, cancer genome
sequencing, exome sequencing, complex disease, Mendelian disorders, personalised genomic medicine
Introduction
Substantial progress has been made in human gen-
etics and genomics research over the past 10 years
since the publication of the draft sequence of the
human genome.1,2 The Human Genome Project
(HGP) provided the basic raw DNA sequence that
spawned a plethora of secondary studies which
together greatly improved our knowledge of the
architecture and function of the genome, yielding
new insights with respect to (i) gene number and
density, (ii) non-protein-coding RNA genes (or
RNA genes), (iii) pervasive transcription, (iv) high
copy number repeat sequences and (v) evolutionary
conservation. These developments also have chal-
lenged the classical definition of the gene (see
below).
In parallel, the design of studies investigating
complex diseases and traits has gradually shifted
from candidate-gene association and linkage studies
to genome-wide association studies (GWASs). The
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first proper GWAS study was published in 2005.
This succeeded in identifying a common risk
variant with a large effect size in the complement
factor H (CFH) gene, which was associated with
age-related macular degeneration.3 By 2007,
approximately 100 new GWASs had been pub-
lished, relating to various complex diseases and
traits.4 There has, however, been some criticism of
the inability of GWASs to identify many of the pre-
sumed disease-associated variants. Indeed, the val-
idity of the common-disease common-variant
(CD/CV) model has recently been challenged by
virtue of the perceived ‘missing heritability’.5–7
This notwithstanding, the GWAS approach has dra-
matically changed the field of human disease gen-
etics, from identifying mostly irreproducible disease
associations in the pre-GWAS era to revealing thou-
sands of statistically robust single nucleotide poly-
morphism (SNP) associations today.8–11 The focus
has also gradually shifted back to Mendelian dis-
orders, with the advent of high-throughput
sequence capture and sequencing technologies
which have potentiated exome and whole-genome
(re)sequencing (WGS).12–16
The rapid advances made in genotyping technol-
ogies over the past decade, from the arrival of the
first ‘whole-genome’ SNP genotyping array (the
Affymetrix GeneChip 10K [Affymetrix; Santa
Clara, CA] in 2003) to current capacity able to
genotype five million SNPs per array (Illumina
Omni5.0 Beadchip [Illumina; San Diego,
CA]),17,18 have contributed substantially to GWASs
(http://www.genome.gov/gwastudies). A total of
874 publications and 4,327 SNP associations with
p-values ,1.0  1025 for approximately 500
complex diseases and traits had been included in
the catalogue as of 13th May 2011.
The genotyping arrays have also contributed
significantly to population genetics studies.19–21
These arrays have been used to identify and
characterise copy number variations (CNVs)22,23
and regions of homozygosity (ROHs).24,25
Research on CNVs and ROHs has also pro-
gressed rapidly since CNVs were first reported to
be widespread in the human genome,26,27 and
ROHs have been found to be common in
outbred populations.28 In recognition of the pro-
gress achieved in the context of both GWASs
and CNVs, ‘human genetic variation’ was con-
sidered the ‘Breakthrough of The Year’ in 2007
by Science.4
Advances have also been made in sequencing
technologies, with the advent of the first next-
generation sequencer in 2004 (Roche GS 20
System [Roche 454; Branford, CT]) and later,
third-generation sequencing (TGS) technologies
such as true single molecule sequencing
(Helicos Biosciences, Cambridge, MA) and
single molecule real-time sequencing (SMRT)
(Pacific Biosciences Menlo Park, CA).29–33
Developments of other more promising TGS or
single-molecule sequencing technologies are on
the horizon, such as nanopore sequencing and
sequencing using transmission electron
microscopy.32,34–37 These developments have also
marked the end of the era of the Sanger dideox-
ynucleotide or chain termination sequencing
method, which has dominated the field since its
introduction in 1977.38
The arrival of next-generation sequencing (NGS)
technologies has also significantly changed the
approaches applied in structural and functional geno-
mics studies. Several microarray-based methods have
been swiftly supplanted by sequencing-based
approaches such as ChIP-Seq, RNA-Seq,
Methyl-Seq and CNV-Seq (paired-end mapping
[PEM] and depth-of-coverage approaches). Studies
using these sequencing approaches have contributed
significantly to both fields.39–41 In addition to a
variety of different applications in functional genomic
studies, these sequencing technologies have also made
it feasible, both technically and in terms of cost, to
sequence a whole human genome within weeks, for
tens rather than hundreds of thousands of US
dollars.42,43 Currently, the cost of WGS at several
tenfold depth of sequencing coverage has been
reduced to less than 5,000 US dollars.44 The number
of WGS studies for both normal and cancer genomes
has grown rapidly over the past three years.45 These
studies have led to important discoveries in the
context of both heritable genetic variation42,43,46 and
somatic mutations in cancer genomes.47–49
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Such progress would not have been possible
without the reference genome generated by the
HGP. Also made possible by the high-
throughput genotyping and sequencing technol-
ogies, several large-scale international projects
have been launched, such as the International
HapMap Project; the Encyclopedia of DNA
Elements (ENCODE) Project, the 1000
Genomes Project, the International Cancer
Genome Consortium, the National Institute of
Health (NIH) Roadmap Epigenomics Program
and the Human Microbiome Project. These pro-
jects have contributed substantially to our under-
standing and knowledge of human genetics and
genomics.
This paper aims to review these major develop-
ments in human genetics and genomics over the
past decade. Major developments and landmarks in
human genetics and genomics are summarised in
Table 1.
The HGP
Rapid progress has been made since the com-
pletion of the HGP, with the provision of a ‘fin-
ished’ reference DNA sequence for the human
genome.64 The project was initiated in 1990 and,
upon its completion in 2003 it yielded important
new insights into the architecture and function of
the human genome. The sequencing of the HGP
relied almost entirely upon the Sanger sequencing
method.
The draft sequences of the HGP were imperfect
because of the incomplete coverage of the euchro-
matic regions (euchromatin) — approximately 10
per cent of these regions were missing. In reality,
the coverage was even less complete when the
whole genome was considered (ie when the het-
erochromatic regions were included). Thus, in all,
some 30 per cent of the genome was not initially
covered. Furthermore, there was an extensive
number of gaps between contigs, which rendered
the genome sequence discontinuous.1,2 The
IHGSC subsequently published an improved
version of the human genome sequence in 2004
and the HGP was then deemed to be ‘complete’.
This ‘finished’ version of the genome had achieved
an almost complete coverage of all the euchromatic
regions (ie approximately 99 per cent) and also sig-
nificantly reduced the number of gaps between
contigs to 341 from the initial hundreds of
thousands.64
Significant further progress toward the total
completion of the human genome sequence con-
tinued until 2006; the complete euchromatic
sequences of all individual human chromosomes,
including the annotation of genes and other fea-
tures, have now been published (summarised in
Table S1). Since November 2005, the National
Center for Biotechnology Information (NCBI)
Build 36 assembly of the human genome sequence
has been available in public databases. The data
comprise a reference assembly of the complete
genome sequence plus the Celera WGS (Celera;
Alameda, CA) and a number of alternative assem-
blies of individual haplotypic chromosomes or
regions. The full list of assemblies in NCBI 36, as
well as the genome sequences, is available through





Although both HGP and Celera Genomics had
only sequenced the human haploid genome, the
availability of the reference DNA sequence
initiated a new era in the study of genetic variation
and the functional characterisation of the human
genome. The two global projects that subsequently
ensued were the International HapMap Project
and the ENCODE project.63,65 The aim of the
HapMap initiative was to validate several million
SNPs that were identified during and after the
completion of the HGP, and then to characterise
the extent of their linkage disequilibrium (LD)
patterns in populations of European, Asian and
African ancestry. The ENCODE project was con-
ceived to identify all the functional and regulatory
elements in the human genome.
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Table 1. Major developments and landmarks in human genetics and genomics, 1977 to date
Year Development References
1977 Sanger dideoxynucleotide/chain termination sequencing method developed 38
Mammalian genes shown to contain introns 50
1978 First report of characterisation of gross gene deletions responsible for human inherited disease
(a- and b-thalassaemia) by Southern blotting
51
1979 First single base-pair substitution causing a human inherited disease (b-thalassaemia) characterised
by DNA sequencing
52
1980 Construction of a genetic linkage map in humans using restriction fragment length polymorphisms 53
1990 Initiation of the Human Genome Project (HGP) 54
1992 Second-generation linkage map of the human genome 55
1996 The Human Gene Mutation Database (HGMD), an attempt to collate known (published)
gene lesions responsible for human inherited disease, established and made available at
http://www.hgmd.org
56
Genome-wide association studies (GWAS) approach for genetic studies of complex diseases
first proposed
57
2001 Completion of draft DNA sequences of the human genome by the International Human Genome
Sequencing Consortium (IHGSC) and Celera Genomics
1,2
International SNP Map Working Group identifies 1.42 million SNPs in the human genome 58
Genetic architecture of complex diseases subjected to intense debate 59,60
Linkage disequilibrium (LD) patterns documented between SNPs in regions of the human genome 61,62
2003 Initiation of the International HapMap Project 63
First whole-genome SNP genotyping array – Affymetrix GeneChip 10K 17
2004 IHGSC publishes the ‘finished version’ of the DNA sequence of the human genome 64
Initiation of the ENCODE project 65
Discovery of hundreds of copy number variations (CNVs) in the human genome 26,27
Database of Genomic Variants (DGV) established to catalogue CNVs 27
First new-generation sequencing (NGS) technology – Roche 454 GS 20 System 29,30
2005 Completion of the International HapMap Phase I Project 66
First proper GWAS using a commercial whole-genome SNP genotyping array 3
2005-present Rapid developments of whole-genome and custom SNP genotyping arrays and technologies 18
Rapid developments of sequencing technologies 31,33
2006 Discovery of more than 1,000 regions of homozygosity .1 megabase (Mb) in the genomes
of outbred populations
28
First comprehensive map of CNVs in the HapMap populations 22
An initial map of insertion and deletion variants in the human genome 67
Continued
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Table 1. Continued
Year Development References
Illumina sequencing platform commercially marketed 29,30
2007 The first human diploid genome (Craig Venter’s genome) sequenced by the Sanger sequencing
method
68
Completion of the International HapMap Phase II Project and extension to Phase III 69
Genome-wide detection and characterisation of positive selection in human populations 70
Completion of the ENCODE project 71
Explosion of GWAS publications (‘Year of GWAS’), approximately 100 new GWASs 4
‘Human Genetic Variation’ considered to be the ‘Breakthrough of The Year’ in 2007 by Science 4
Sequence capture or enrichment methods and technologies developed 72–74
Pervasive transcription documented 75
Demonstration of paired-end mapping (PEM) to detect structural variation using NGS
technologies
76
Demonstration of ChIP-Seq to map transcription factor binding sites 77
Demonstration of ChIP-Seq to interrogate histone modifications 78
Life Technologies SOLiD sequencing platform commercially marketed 29,30
A community resource project launched to sequence large-insert clones from many individuals,
systematically discovering and resolving these complex variants at the DNA sequence level




Microarray-based methods increasingly supplanted by sequencing-based approaches such
as ChIP-Seq, RNA-Seq, Methyl-Seq and CNV-Seq
39,41,80,81
2008 First human diploid genome (James Watson’s genome) sequenced by NGS technologies 46
First whole cancer genome (acute myeloid leukaemia [AML]) sequenced 82
Initiation of the 1000 Genomes Project 83
Vast majority of human genes shown to undergo alternative splicing (RNA-Seq) 84,85
Large scale mapping and sequencing of structural variation using a clone-based method 86
Demonstration of depth-of-coverage approach to detect CNVs using NGS technologies 87
First GWAS meta-analysis using imputation methods 88
The issue of ‘missing heritability’ in GWASs recognised 89
2009 Feasibility of exome sequencing approach to identify a causal mutation for a Mendelian disorder
first demonstrated
12
Exome sequencing as a useful tool for diagnostic application demonstrated 90
Third generation sequencing (TGS; single molecule sequencing) technology introduced —
Heliscope Single Molecule Sequencer (Helicos Biosciences) commercially marketed
91
Continued
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Table 1. Continued
Year Development References
First human diploid genome sequenced by TGS technology 92
Latest assembly of the human genome (Genome Reference Consortium, release GRCh37,
February 2009), Genebuild published by Ensembl (database version 56.37a) includes 23,616





Large intergenic non-coding RNAs (lincRNAs) found to represent a novel category of
evolutionarily conserved RNAs
93,94
Direct single molecule RNA sequencing without prior conversion of RNA to cDNA 95
First human DNA methylomes at base resolution 96
Comprehensive mapping of long-range chromatin interactions 97,98
2010 Number of disease-causing/disease-associated germline mutations collated in the Human Gene
Mutation Database exceeds 100,000 in .3,700 different nuclear genes
99,100
More than 17 million SNPs in the human genome catalogued in the SNP Database
(dbSNP; http://www.ncbi.nlm.nih.gov/projects/SNP/)
101
As of 2nd November 2010, DGV catalogued 66,741 CNVs, 953 inversions and 34,229 insertions










Completion of the International HapMap Phase III Project 21
Completion of pilot phase of the 1000 Genomes Project 102
Second generation whole-genome SNP genotyping array (with SNP selection from the





Cost of whole-genome sequencing (at several tenfold of sequencing coverage depth) reduced to
less than $5,000
44
Metagenomic sequencing of human gut microbes accomplished using NGS technologies 103
Exome sequencing study identifies causal mutations and genes for previously unexplained
Mendelian disorders
13,14
GWAS meta-analysis involving total sample size of .249,000 104
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Architecture and function of the
human genome
To coincide with the tenth anniversary of the
release of the draft human genome sequences, the
key findings from the HGP and their importance
for the results of subsequent studies will now be
recalled briefly. The findings emanating from the
HGP and follow-on studies have had an enormous
impact on the understanding of the architecture
and function of the human genome.
Gene number and density
Initial annotation data indicated that the human
genome encodes at least 20,000–25,000 protein-
coding genes, with an indeterminate number of
additional ‘computationally derived genes’ sup-
ported by somewhat weaker in silico evidence.2,64
Many genes are now known to encode RNAs
rather than proteins as their final products117 but
many still remain unannotated.75 In the latest
assembly of the human genome (Genome
Reference Consortium, release GRCh37, February
2009), the Genebuild published by Ensembl (data-
base version 56.37a) includes 23,616 protein-
coding genes, 6,407 putative RNA genes and
12,346 pseudogenes (http://www.ensembl.org/
Homo_sapiens/Info/StatsTable). The HUGO
Human Gene Nomenclature Committee (http://
www.genenames.org/index.html) has so far
approved more than 28,000 human gene symbols,
although some of these may yet turn out to corre-
spond to functionally meaningless open reading
frames.118 It is nevertheless encouraging that at least
17,052 human genes have been shown to have
orthologous counterparts in the mouse genome,
suggesting that they do indeed correspond to real
proteins.119 The definition of what constitutes a
gene is still fairly fluid, and hence, depending upon
the precise definition adopted, it may be that many
Table 1. Continued
Year Development References
Characterisation of 20 sequenced human genomes to evaluate the prospects for identifying rare
functional variants
106
Neanderthal genome sequenced 107
The genome of an extinct Palaeo–Eskimo sequenced 108
Exome sequencing of 200 individuals identifies an excess of low-frequency non-synonymous
coding variants
109
International Cancer Genome Consortium (ICGC) launched 110
Largest GWAS of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls
performed
111
2011 As of 13th May 2011, 874 publications and 4,327 SNPs documented in the National Human




Comprehensive mapping of copy number variations based on whole-genome DNA
sequencing data
112
Developments of other TGS technologies, such as single-molecule real-time sequencing and
nanopore sequencing, are on the horizon
32
New addition to the NGS market — the Ion Torrent Personal Genome Machine (PGM),




Single-cell sequencing to infer tumour evolution 113
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additional human ‘genes’ still remain to be
described and annotated.
To appreciate why definition is an issue here, one
need only be aware of the many exceptions to genes
being contiguous (as well as functionally and spatially
distinct) entities, as classically envisaged. Thus, some
genes are known to occur within the introns of other
genes.120–122 Some genes can overlap with each
other either on the same or on different DNA
strands,123 resulting in the sharing of some of their
coding and/or regulatory elements.124,125 In addition,
the vast majority of human genes are now known to
undergo alternative splicing,84 leading in some cases
to quite different proteins being encoded by the same
gene. For example, the human cyclin-dependent
kinase inhibitor 2A gene (CDKN2A) (MIM#
600160) encodes an alternatively spliced variant
(p14ARF) which, through the inclusion of an alterna-
tive first exon, acquires an altered reading frame so as
to specify a protein product that is structurally unre-
lated to the other p16 isoforms encoded by this gene.
Gene density varies between the human
chromosomes and the gene distribution within
chromosomes is also rather uneven. Strikingly
gene-poor regions have been identified and are
known as ‘gene deserts’.126 These are regions that
are devoid of protein-coding genes over distances
of several Mb but which may nevertheless contain
regulatory sequences (Box 1).
RNA genes or non-protein-coding RNAs
A large proportion of the human transcriptome still
remains to be annotated.136 Although some of the
overall transcriptional activity may simply be ‘tran-
scriptional noise’,137,138 at least a portion of it is
likely to be associated with functional non-coding
RNA genes, many of which are located in regions
previously regarded as intergenic and/or non-
coding.71 Non-coding RNA genes are as widespread
as they are diverse,139 are transcribed from both
strands of the genome and may well exceed protein-
coding genes in terms of their number.140,141
Non-coding RNAs of known function include
structural RNAs such as transfer RNAs, ribosomal
RNAs and small nuclear RNAs, but also putative
Box 1. Gene deserts and their potential relevance to human inherited
disease
A functional role(s) for gene deserts127 has been supported by results from GWASs. Thus, multiple
SNPs on chromosome 5p13.1 have been shown to be strongly associated with Crohn’s disease, even
though the region is located within a 1.2 Mb gene desert and the nearest annotated gene, that encod-
ing prostaglandin E receptor EP4 (PTGER4), is about 270 kb away from the association signals.128–131
Although the SNPs were consistently associated with the disease, their functional effect is not easy to
infer because these SNPs could exert an effect either on the nearest gene or on other genes that are
located further away. However, Libioulle et al. (2007)128 integrated the GWAS results with gene
expression data and found that the associated SNPs influenced the level of expression of PTGER4.
The majority of GWAS-SNPs are located in either intronic, intergenic or gene desert regions rather
than within gene-coding or promoter sequences. These SNPs could nevertheless be of direct functional
significance if their locations coincide with regulatory elements, either already known or yet to be
characterised, such as enhancers, transcription factor binding sites and sequences encoding for
microRNAs.132
The association of the SNP rs6983267 at 8q24 with colorectal and prostate cancer has been a
mystery since its discovery because the risk allele is located in a gene desert .300 kb away from the
nearest annotated gene, MYC. Recent studies have, however, found that the region containing the risk
allele is a transcriptional enhancer that interacts with the MYC proto-oncogene.133,134 In a similar vein,
GWAS-SNPs in a 9p21-located gene desert (associated with coronary artery disease) have been found
to impair the interferon-g signalling response.135
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regulatory RNAs (microRNAs, small interfering
RNAs [siRNAs], piwi-interacting RNAs, tran-
scription initiation RNAs [tiRNAs], transcription
start site-associated RNAs [TSSa-RNAs], promoter
upstream transcripts [PROMPTs], promoter-
associated sRNAs [PASRs and PALRs] and longer
non-coding RNAs such as XIST), which are
involved in sequence-specific transcriptional
and post-transcriptional modulation of gene
expression.142–148 Thus, more than 1,000
microRNA genes already have been identified in
the human genome, with many more probably
awaiting discovery (Box 2). In total, at least 1,500
non-coding RNA genes already have been anno-
tated in the human genome reference sequence,
with up to 5,000 more predicted by homology-
based methods117 (see Ensembl, database version
56.37a).
Indeed, large intergenic non-coding RNAs
(lincRNAs) recently have been found to represent
a novel category of evolutionarily conserved
RNAs, with a diverse array of functions ranging
from stem cell pluripotency to cellular prolifer-
ation;93,94 lincRNAs appear to number at least
3,000 in the human genome.155–158 Some
lincRNAs guide chromatin-modifying complexes
to specific genomic loci, to regulate gene
expression.94 LincRNAs also play an important role
in the derivation of human-induced pluripotent
stem cells.156 Collectively, non-coding RNAs have
been intensively studied over the past several
years.159,160
Pervasive transcription: Transcripts of
unknown function and unannotated
transcripts
The ENCODE project, designed to analyse 30 Mb
of DNA from 44 genomic regions to characterise
the functional elements present, has identified
complex patterns of regulation and ‘pervasive tran-
scription’ of the human genome.71 Although .90
Box 2. MicroRNAs
MicroRNA has been the most intensively studied non-coding RNA in the human genome. MicroRNA
gene loci may be fairly numerous: already more than 15,000 microRNA gene loci have been identified
in various species (miRBase, Release 16.0: September 2010; http://www.mirbase.org/), with 1,048
microRNAs being found in the human genome.
Biogenesis and function
The synthesis of microRNAs starts with the transcription of primary microRNAs by RNA polymerase
II. The primary microRNAs will be processed further to become precursor microRNAs and then
mature microRNAs. The mature microRNAs are short sequences of 18–25 nucleotides; they are
incorporated into RNA-induced silencing complex (RISC) to exert their post-transcriptional regulat-
ory roles through binding to the 30 untranslated region (UTR) of target mRNAs. The binding of
microRNA to target mRNAs can lead to two possible outcomes; either degradation or cleavage of the
mRNAs or suppression of the translation of mRNAs into protein.149
Relevance to diseases
The importance of microRNAs as functional regulators increasingly has been interrogated by microar-
ray and sequencing studies. Deregulation in the expression patterns of microRNAs was commonly
associated with various cancers.150–152 SNPs in the (i) sequences encoding microRNAs and (ii) 30
UTR of mRNAs also have been found to be associated with various cancers.153,154
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per cent of the human genome appears to be rep-
resented in nuclear primary transcripts, it has
become clear that only 35–50 per cent of pro-
cessed transcripts have so far been annotated as
genes, implying that many genes may not yet have
been recognised as such.71,85,161,162 Thus, large
numbers of hitherto unannotated transcripts may
well yet turn out to be of functional significance.161
Such transcripts have been collectively classified as
transcripts of unknown function (TUFs) and are
thought to include (i) antisense transcripts of
protein-coding genes, (ii) isoforms of protein-
coding genes and (iii) transcripts that either overlap
introns of annotated gene transcripts (on the same
strand) or which are derived entirely from inter-
genic regions. Although both the complexity and
abundance of TUFs are remarkable, it should be
realised that there is often no firm evidence for
these transcripts being of functional significance.
Indeed, unannotated non-polyadenylated transcripts
originating from intergenic regions have been
found to represent the bulk of the .90 per cent of
the human genome that now appears to be tran-
scribed.161,163,164 Although the functional signifi-
cance of pervasive transcription remains unclear, it
is much more extensive than had previously been
realised.165
In both humans and mice, up to 70 per cent of
genomic loci exhibit evidence of transcription from
the antisense strand, as well as the sense strand.166–
168 These naturally occurring antisense transcripts
may modulate the level of expression of their
associated sense transcripts (or otherwise influence
their processing), thereby adding another level of
complexity to the regulation of gene
expression.169,170 Although there is, as yet, no sug-
gestion that the genomic sources of such antisense
transcripts should be regarded as genes in their own
right, their prevalence clearly renders our task of
defining the gene that much more difficult.
High copy number repeat sequences
The HGP revealed that repeat sequences account
for at least 50 per cent of the human genome
sequence. These repeats may be classified as (i)
transposon-derived repeats, (ii) partially retroposed
copies of genes (referred to as processed pseudo-
genes), (iii) simple sequence repeats, (iv) blocks of
tandemly repeated sequences at centromeres, telo-
meres and the short arms of acrocentric chromo-
somes and (v) segmental duplications (SDs) or low
copy number repeats.
Segmental duplications
Both the number and the breadth of the distri-
bution of SDs in the human genome (5 per cent)
were surprising. SDs represent extensive inter- and
intra-chromosomal duplications of genomic regions
that contain genes as well as intergenic
sequences.1,2 She et al. extended the initial analyses
of these low copy number repeats or SDs and
initiated the characterisation of the duplicational
landscape of the human genome.171 SDs may be
viewed as mutational hotspots, since they are prone
to aberrant recombination events occurring
between highly homologous paralogous SDs, and
give rise to large deletions or duplications of the
intervening sequences resulting in human genomic
disorders.172 Indeed, SDs have been shown to rep-
resent frequent sites of CNV between individuals,
thereby contributing considerably to human
genomic diversity.173 The mechanism that generates
CNVs in SDs is known as non-allelic homologous
recombination.174 These interspersed SDs confer
susceptibility to recurrent microdeletions and
microduplications upon approximately 10 per cent
of the human genome through unequal crossing
over. Furthermore, data have accumulated showing
that specific recurrent rearrangements within these
genomic hotspots are associated with both syndro-
mic and non-syndromic diseases. Studies of
common complex diseases have shown that these
recurrent events play an important role in autism,
schizophrenia and epilepsy.175–177
The above notwithstanding, the duplicated
genomic regions have remained largely intractable,
owing to difficulties in accurately resolving their
structure, copy number and sequence content.
New algorithms have been developed to map com-
prehensively next-generation sequence reads, allow-
ing the prediction of absolute CNVs of duplicated
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segments and genes. On average, 73–87 genes vary
in copy number between any two individuals and
these differences overwhelmingly correspond to
segmental duplications.178
Pseudogenes
Whether processed or non-processed (duplica-
tional), it has become clear that pseudogenes are
almost as abundant as genes (‘classical’ or otherwise)
in the human genome, with 20 per cent of
known pseudogenes being transcribed.179–181 By
means of a comparison of cytochrome P450 genes
(CYP) from the mouse and human genomes,
Nelson et al. (2004) demonstrated that the complete
identification of all human pseudogene sequences is
likely to be clinically important and proposed a
naming procedure for CYP pseudogenes.182
It should, however, be appreciated that, although
some pseudogenes may well be readily identifiable as
lacking protein-coding potential by virtue of the
interruption of their open-reading frames by prema-
ture stop codons or frameshift mutations, others will
be less easily recognisable, especially if they are tran-
scribed. The recent identification of short (300 bp)
human pseudogenes generated via the retrotransposi-
tion of mRNAs,183 however, suggests that pseudo-
genes may be even more common in the human
genome than previously appreciated. Intriguingly,
some of these pseudogenes are polymorphic, in that
they have functional as well as non-functional alleles
segregating in the extant human population.184
With the realisation that pseudogene-derived
RNA transcripts may harbour functional
elements,181,185 the distinction between genes and
pseudogenes has become somewhat blurred.186
Indeed, some ‘pseudogenes’ appear to have a regulat-
ory role,187,188 providing additional examples of the
potential functional significance of non-coding
RNAs. At present it is unclear what proportion of the
pseudogenes identified to date have either retained or
acquired a function via their non-coding RNAs.
Transposable elements
Transposable elements, including Long INterspersed
Elements (LINE-1), Alu and SINE–VNTR–Alu
(SVA) elements (SVA is an unusual composite element
derived from three other repeats: Short INterspersed
Elements [SINE]-R, variable number tandem repeats
[VNTR] and Alu), make up 40 per cent of the
human genome189 and constitute a major source of
inter-individual structural variability.190 Some of these
transposable elements have contributed gene-coding
sequences to the human genome via ‘exonisation’.191
Other transposable elements have contributed func-
tional non-coding sequence — for example, as regu-
latory elements,192,193 microRNAs194 or naturally
occurring antisense transcripts.195 Many more are
likely to have functional significance, as suggested by
their evolutionary conservation.196,197
Evolutionary conservation
Extensive evolutionary conservation of non-coding
DNA sequences is evident in the human genome
because only 40 per cent of the evolutionarily
constrained sequence occurs within protein-coding
exons or their associated untranslated regions.71
Studies of evolutionarily conserved non-coding
sequences198–201 have suggested that 5–20 per cent
of the genome may be of functional importance,
rather than just the 2 per cent associated with the
protein-coding portion.202,203 Some non-coding
regions (the genomic ‘dark matter’) contain ‘ultra-
conserved elements’ which not only exhibit enhan-
cer function, but are also transcribed and often
appear to have been subject to selection to the
same extent as protein-coding regions.204–206
Some non-coding regions contain CpG islands,
which, although located far from the transcriptional
initiation sites of genes, may nevertheless have
some regulatory significance.207 It should be
appreciated, however, that the absence of evol-
utionary conservation does not necessarily denote
lack of function. Indeed, human specific functional
elements have been shown to be present within
rapidly evolving non-coding sequences.208,209
Towards a new definition of the gene
It is clear from the above that precisely what consti-
tutes a gene has become somewhat contentious.
The unanticipated scale of the extent of
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transcription in the genome, coupled with the
widespread occurrence of overlapping genes and
shared functional elements, hampers attempts to
demarcate precisely and unambiguously where one
gene ends and another one begins. As a conse-
quence, the notion of the gene has become
diffuse.161,210 Indeed, as Kapranov et al.211 opined,
‘it is not unusual that a single base-pair can be part
of an intricate network of multiple isoforms of
overlapping sense and antisense transcripts, the
majority of which are unannotated’. Gene regulat-
ory elements that are often distant from the genes
they regulate,212 the existence of trans- as well as
cis-regulatory elements213 and the formation of
non-co-linear transcripts through trans-splicing,214
taken together with the abundance of non-coding
RNA genes215 and evolutionarily conserved non-
coding regions,199,201 have combined to challenge
the classical notion of the gene.
On the basis of the findings of the ENCODE
project, Gerstein et al.210 proposed an updated defi-
nition of the gene as ‘a union of genomic sequences
encoding a coherent set of potentially overlapping
functional products’. An alternative definition of the
gene as: ‘A discrete genomic region whose transcrip-
tion is regulated by one or more promoters and distal
regulatory elements and which contains the infor-
mation for the synthesis of functional proteins or non-
coding RNAs, related by the sharing of a portion of
genetic information at the level of the ultimate pro-
ducts (proteins or RNAs)’ has been proposed by
Pesole.216 Irrespective of its precise definition, it is
clear that the concept of the gene is inadequate to the
task of building a lexicon of those functional genomic
sequences that could harbour mutations causing
human inherited disease. It is likely in the context of
mutation detection, that we shall eventually have to
consider the universe of functional genetic elements
in the human genome as our hunting ground, rather
than simply genes per se.
Development of the GWAS approach
to complex diseases and traits
In this section, developments in cataloguing genetic
variation (SNP and CNV), initiation and
completion of the International HapMap Project,
and advances in genotyping technologies are dis-
cussed. These developments are important prere-
quisites for the use of GWASs in the investigation
of complex diseases and traits.
SNP discovery after the HGP
While the HGP was being completed, genetic var-
iants, in particular SNPs, were also being discov-
ered. By 2001, the International SNP Map
Working Group had identified 1.42 million SNPs
in the human genome.58 Currently, more than 17
million SNPs in the human genome have been cat-
alogued in the SNP Database (dbSNP; http://www.
ncbi.nlm.nih.gov/projects/SNP/). It is, however,
likely that at least some of the entries in the database
are errors or artefacts rather than ‘genuine’ variants.
A false-positive rate for the dbSNP of 15–17 per
cent has been estimated.101 Therefore, large-scale
validation in population-based studies is necessary.
The HapMap Project was conceived in 2003 with
the aim of validating several million SNPs in order
to obtain SNP and genotype frequency information,
as well as to study their LD patterns in different
populations.
SNPs are the most abundant type of genetic
variation in the human genome. They occur at
intervals of approximately one SNP to every kb of
DNA sequence throughout the genome when the
DNA sequences of any two unrelated individuals
are compared. This is approximately equivalent to
three million SNPs being carried by each individual
genome. Therefore, the DNA sequences of any
two unrelated genomes are estimated to be about
99.9 per cent identical; the 0.1 per cent comprises
mainly SNPs, and these are believed to be respon-
sible for many of the phenotypic differences noted
among individuals in populations — for example,
disease susceptibility, drug responses and physical
traits such as height.217
The discovery of thousands of CNVs that collec-
tively encompass hundreds of Mb of the
genome22,23,105 and the several hundred thousand
short indels identified by WGS studies,42,43
however, have cast doubt upon the initial estimate
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of ‘99.9 per cent similarity’ between any two
genomes. Indeed, the DNA sequences of individ-
uals within and between populations are genetically
rather more diverse and varied than previously
thought. This has been corroborated by a recent
study demonstrating that the Craig Venter genome
differs from the consensus reference sequence by
approximately 1.2 per cent when indels and CNVs
are considered, a further 0.1 per cent when SNPs are
considered and 0.3 per cent when inversions are
considered — a grand total of 1.6 per cent.218
Linkage disequilibrium and the International
HapMap Project
Most SNPs are predicted to be neutral, without
any functional effects. Owing to their abundance
in the human genome, they may serve as useful
genetic markers in GWASs, by comparison with
other genetic variations, such as microsatellites,
which in any case exhibit a mutation rate that is
too high to be useful in this context. Early reports
documented LD patterns between SNPs in parts of
the human genome;61,62,219 however, no large-scale
effort had been undertaken to study the LD pat-
terns in the whole genome until the initiation of
the International HapMap Project. A total of more
than three million SNPs were genotyped and vali-
dated in Phase I and Phase II of the project in four
populations.66,69 These populations were the US
Utah population of Northern and Western
European ancestry (CEU), Han Chinese from
Beijing (CHB), Japanese from Tokyo (JPT) and the
Yoruba from Ibadan, Nigeria (YRI).
One novel finding has been that 10–30 per cent
of pairs of individuals within a population share at
least one region of extended genetic identity arising
from recent common ancestry. An additional dis-
covery was that up to 1 per cent of all common
variants are not tagged by SNPs, primarily because
they are located within recombination hotspots.69
Importantly, increased population differentiation
with respect to non-synonymous SNPs was noted,
by comparison with synonymous SNPs. These
observations have also indicated systematic differ-
ences in the strength or efficacy of natural selection
between populations from different geographical
areas involving genes linked to the Lassa virus in
West Africa, skin pigmentation in Europe and hair
follicle development in Asia.70
The discovery of millions of SNPs has created a
significant challenge in genotyping. It is neither
technically feasible nor cost-effective to genotype
all the SNPs in a GWAS, even with the latest geno-
typing technologies; however, the existence of LD
significantly reduces the number of SNPs that need
to be genotyped. The indirect association approach
of GWASs is dependent on surrogate markers (‘tag’
SNPs) to locate disease variants through LD. As
shown by the HapMap Project69 and other pub-
lished work,220–222 approximately half a million
SNPs are adequate to capture most of the SNPs
that have been genotyped in the HapMap Phase I
and II projects. However, the genome coverage of
commercial genotyping arrays is population depen-
dent (Box 3).
The HapMap project has created a useful and
valuable resource for GWASs. In parallel, the public
availability of the HapMap resource has driven the
rapid development of genotyping arrays, in which
the data are used to guide the selection of tag
SNPs. Once the HapMap Phase I and II projects
were completed, a number of genotyping arrays
were designed and introduced onto the
market.223,224 The newer arrays (eg the Illumina
Human 1M Beadchip and Affymetrix SNP Array
6.0) have significantly improved genome coverage
and are also designed for CNV detection.225 The
HapMap Phase I and II projects led to the develop-
ment of higher resolution genotyping arrays, which
in turn were used in the HapMap Phase III project
to investigate genetic variations (both SNPs and
CNVs) in additional populations of diverse
ancestry.21
The Phase III project, building on the success of
the HapMap Phase I and II projects, included an
additional seven populations and has recently been
completed.21 These additional populations involved
people of African ancestry in the south-western
USA (ASW), the Chinese community in
Metropolitan Denver, CO (CHD), Gujarati Indians
in Houston, TX (GIH), the Luhya in Webuye,
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Kenya (LWK), people of Mexican ancestry in Los
Angeles, CA (MEX), the Maasai in Kinyawa,
Kenya (MKK) and Tuscans in Italy (TSI). The
ethos behind the HapMap Phase III project was
that, in order to obtain a more complete under-
standing of human genetic variation, populations
with a wider geographical/ancestral range needed
to be studied. In total, the HapMap Phase III
project genotyped approximately 1.6 million SNPs
(using both the Illumina Human 1M Beadchip and
Affymetrix SNP Array 6.0) in 1,184 individuals
from 11 populations (four original and seven
additional populations). The population-specific
differences among low-frequency variants were
characterised in addition to SNPs and common
CNVs or copy number polymorphisms (CNPs).
More importantly, it also demonstrated the feasi-
bility of imputing newly discovered CNPs and
SNPs, which are important for future GWASs and
meta-analyses.21
Whole-genome SNP genotyping technologies
The paradigm shift from candidate-gene association
and family linkage studies to GWASs has been
attributed to several important developments, most
notably the rapid advances in high-throughput
SNP genotyping technologies, which have enabled
researchers to interrogate up to one million SNPs
simultaneously in a microarray.18 GWASs employ
an ‘agnostic’ approach in the search for unknown
disease variants, and hence the ability to interrogate
a large number of SNPs covering the entire human
genome is a prerequisite for this study design. In
parallel with the decreasing cost of genotyping, it
has recently become technically feasible to geno-
type thousands of samples in GWASs. As a result,
more than 800 GWASs have been published since
2005 (http://www.genome.gov/gwastudies/), of
which almost all have used the commercially avail-
able whole-genome SNP genotyping arrays from
Illumina or Affymetrix.
A series of whole-genome genotyping arrays
have been introduced since 2005, such as the
Affymetrix Human Mapping 100K 500K sets, and
the Illumina HumanHap300 and HumanHap550
BeadChips.223,224 These genotyping arrays provide
different degrees of genome coverage in different
populations; lower coverage was achieved in
African populations because of the greater genetic
diversity in these populations. For example, the
Illumina HumanHap550 Beadchip, which contains
approximately 550,000 tag SNPs selected from the
HapMap Phase I and II projects, achieved genome
coverage of 87 per cent and 83 per cent in CEU
and CHB þ JTP populations, respectively, but only
50 per cent in YRI.220–222 Whole-genome geno-
typing arrays such as the Illumina Human 1M
Beadchip and Affymetrix SNP Array 6.0 offer almost
complete genome coverage (.90 per cent) for
HapMap CEU and CHB þ JPT populations (Box 3).
The more recent genotyping arrays, such as the
Illumina Human 1M BeadChip and Affymetrix
SNP Array 6.0, have enabled genotyping of up to
one million SNPs and increased the sensitivity to
detect CNVs because of higher marker density and
more uniform marker distribution.225 For example,
the Affymetrix SNP Array 6.0 contains more than
Box 3. Genome coverage
High genome coverage is important, since the underlying principle of this approach is the use of LD to
detect disease variants. In SNP-scarce regions, bona fide disease variants could be missed because they
are not in strong LD with any of the SNPs genotyped on the array. Genome coverage is an estimate of
the proportion of SNPs (using the International HapMap data as a reference) that can be captured by
the SNPs which are directly genotyped in an array with a preset r2 threshold. Usually, a threshold of
0.8 is used to estimate genome coverage. These first-generation genotyping arrays used the
International HapMap database for SNP selection and have poor coverage for SNPs with minor allele
frequency (MAF) ,5 per cent.220–222
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1.8 million markers, half of which are SNPs, the
remainder being non-polymorphic or copy number
probes to enhance the power of detection of
CNVs. Copy-number probes were deliberately
selected so as to cover regions lacking SNPs or
regions where SNPs are difficult to assay, such as
repetitive sequences within segmental dupli-
cations.226 In addition, markers were also chosen to
target known copy number variable regions as
reported in the Database of Genomic Variants
(http://projects.tcag.ca/variation/). Employing such
a design, these genotyping arrays have enabled
researchers to discover novel CNVs, as well as to
validate previously known CNVs. These more
recent arrays were designed for the application of
GWASs and CNV detection.
The first wave of GWASs utilised first-generation
SNP genotyping arrays and focused mainly on
common SNPs with MAF .5 per cent.132 Thus,
expanding the coverage to include less common or
rarer SNPs (MAF 1–5 per cent) is essential for new
discoveries to be made in future GWASs. This step
is now technically feasible and practically achievable
with the arrival of second-generation SNP geno-
typing arrays (Illumina HumanOmni2.5 and
Omni5.0) in 2010; these are capable of genotyping
2.5 to 5.0 million SNPs (Illumina Whole-Genome
Genotyping Product Roadmap; http://www.
illumina.com/applications/gwas.ilmn). These arrays
were designed to increase the coverage of SNPs
down to a MAF of 1 per cent. In contrast to the
first-generation arrays, the SNP selection in these
latest genotyping arrays leverages the data from the
1000 Genomes Project.102 However, the promise
of second-generation genotyping arrays for new
discoveries in GWASs is conditional upon the ade-
quacy of the statistical power of the studies to ident-
ify the associations of rarer SNPs with complex
traits. This suggests that larger sample sizes will be
needed in future GWASs.
The era of GWASs
More than 4,000 SNPs have been reported to be
associated with various human complex diseases
and traits with varying degrees of replication and
success (http://www.genome.gov/gwastudies/).
Despite some notable successes in revealing
numerous novel SNPs and loci associated with
complex phenotypes, the results from GWASs have
been disappointing, in that all the GWAS-SNPs
collectively account for only a small proportion of
the heritability of complex phenotypes. This is due
mainly to the small effect sizes of most
GWAS-SNPs (odds ratio ,1.5).5,10,89 The small
effect sizes of the GWAS-SNPs have also limited
their applications in disease risk prediction.227
Although several diseases have been claimed to
be investigated by GWASs and meta-analyses of suf-
ficiently large sample sizes, most of their heritability
still remains unaccounted for. This missing herit-
ability has stimulated much discussion on future
strategies for detecting the remaining genetic var-
iants associated with complex phenotypes. The
proposed strategies range from increasing the
sample sizes by combining several GWASs through
meta-analysis in order to attain a higher statistical
power, to more complicated experiments such as
epigenetic studies.5,228 The methodologies for
meta-analysis and for the merging of SNP geno-
type data from multiple GWASs employing differ-
ent genotyping arrays are now well developed and
rely upon newly developed genotype imputation
methods.229–231 By contrast, there are still many
experimental and analytical uncertainties and chal-
lenges to be faced in the context of epigenetic
studies of complex phenotypes.232,233 Other
approaches are summarised in Figure 1.
Figure 1 summarises a variety of approaches to
the further identification of disease-associated var-
iants: (1) GWASs of various complex diseases and
traits ideally should be performed in different
populations representing European, Asian and
African ancestries, as most published studies have
focused primarily on populations of European
ancestry.234,235 (2) Most GWASs have done fast-
track replication by selecting the top few or top
tens of SNPs with the most significant p-values in
stage 1 and then proceeded to replicate them in
stage 2 or stage 3 with larger sample sizes.
Therefore, the next step should be to conduct a
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second tier of replication, where more SNPs from
stage 1 are tested to assess their associations.236 (3)
The role of CNVs is increasingly recognised as
being associated with complex diseases and traits;
thus, it is important to investigate their associations
with these complex phenotypes.111 (4)
Resequencing of the GWAS loci will be needed to
uncover additional rarer variants. The success of
this approach has been demonstrated in the discov-
eries of multiple rare variants for type 1 diabetes
and hypertriglyceridaemia.237,238 (5) Integrating
GWAS results with other sources of genomic data,
such as expression quantitative trait loci (eQTL)
and ChIP-Seq, has led to the discovery of novel
SNP associations.239,240 (6) Subgroup analysis of
disease phenotypes is a powerful approach to identify-
ing genetic variants that are specific to certain sub-
types. For instance, differences in SNP associations for
oestrogen receptor-positive and -negative breast
cancer have been shown.241 (7) Pathway-based
approaches have been developed using prior biological
knowledge of gene function to facilitate more power-
ful analysis of GWAS datasets.242 (8) Most studies have
not taken epistasis and gene–environment interactions
into account, which could account for a proportion
of the missing heritability of complex phenotypes;
however, challenges associated with studying these
interactions should also be noted.243,244
Genetic architecture of complex diseases
The genetic architecture of complex diseases has
been the subject of intense debate over the past
decade59,60 and has been polarised by the emer-
gence of two opposing models: the CD/CV
hypothesis and the multiple rare variant or common-
disease rare-variant (CD/RV) hypothesis.245 The
CD/CV model formed the basis of the HapMap
Project and largely influenced the development of
commercial genotyping arrays with respect to SNP
selection. Therefore, the published GWAS using the
HapMap data mainly involved the interrogation of
the association of common SNPs (MAF. 5 per
cent) with complex diseases and traits.
One of the reasons that the CD/CV model
became favoured was because of the sequencing
technologies available at that time. Sanger sequen-
cing did not allow the survey of rare variants in the
whole genome. By contrast, the convenient high-
throughput genotyping platforms have enabled
efficient interrogation of up to one million
SNPs throughout the genome, which eventually
indirectly leads to the capture of almost all the
SNPs in the HapMap Project. Furthermore, it is
more affordable to genotype (rather than to
sequence) the entire genomes of several thousand
cases and controls as part of an adequately powered
association study.
Figure 1. Summary of the approaches identifying disease-associated variants.
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Currently, the results from the GWASs focus on
common SNPs and explain only a small fraction of
the heritability of complex phenotypes.5 The
missing heritability has challenged the validity of
the CD/CV hypothesis, and has also diverted
research endeavours toward rare var-
iants;109,237,238,246,247 however, published data have
revealed the contributions of both common and
rare variants to complex phenotypes. The results
from GWASs have strongly supported the involve-
ment of common variants, especially common
SNPs, in complex phenotypes.132 Moreover, recent
studies have shown that common SNPs can explain
a greater proportion of the heritability than has
been accounted for by recent GWASs. These
SNPs, however, are often ‘hidden’ within the
GWAS data, and will require larger sample sizes to
be uncovered.248,249
The data supporting the roles of rare variants
have also been accumulating from an increasing
number of studies of less-common
SNPs109,237,238,246 and rare CNVs.250–253 This
suggests that the genetic architecture of complex
phenotypes is likely to comprise both common and
rare variants. The relative proportions of these var-
iants remain to be determined and will remain
unclear until all the genetic variants for most
complex phenotypes are found; furthermore, the
relative proportions are likely to vary between
different complex phenotypes, with some pheno-
types having a greater influence on the genetic sus-
ceptibility risk by common variants, whereas other
phenotypes may be more affected by rare variants.
Being able to predict the genetic architecture of
complex phenotypes is critical, however, as it will
determine the future strategies to be adopted in
seeking disease variants.
Homozygosity mapping
Homozygosity mapping has been shown to be
useful in the identification of disease susceptibility
genes in complex diseases.254,255 An ROH defines
an uninterrupted stretch of a DNA sequence
lacking heterozygosity in the diploid state (ie in the
presence of both copies of the homologous DNA
segment). Thus, all the genetic variants within the
homologous DNA segments are represented by
two identical alleles that contribute to the homo-
zygosity.28 Currently, there are no standardised cri-
teria to define an ROH. Previous studies have
focused on regions 1 Mb, however, and hence
the true extent of homozygosity in the human
genome could have been underestimated because
shorter regions were not considered.28,256,257 More
recent studies have defined ROHs as having a
minimum length of 500 kb,258 the intention being
to avoid underestimation of the number of such
regions in the human genome.
Although long continuous ROHs were first
documented a decade ago, until recently no
large-scale population-based studies had been per-
formed to assess the extent of ROHs in the human
genome.259 The recent advances in the genome-
wide detection and characterisation of ROHs have
been driven mainly by the availability of highly
accurate SNP databases such as the HapMap
project28 and advanced genotyping technol-
ogies.24,25 Genotyping a large number of SNPs on
a microarray platform presents a powerful tool for
detecting ROHs comprehensively across the whole
genome, thereby enabling investigation of the
number, length, location and distribution of the
ROHs in the human genome in a more unbiased
manner, as compared with microsatellite markers. It
was not previously expected that the genomes of
outbred populations would contain ROHs of
several Mb in length until the early reports
appeared in 2006/2007.28,256,257
Many novel causal genes or mutations under-
lying autosomal recessive disorders have been ident-
ified through homozygosity mapping. This
approach is particularly useful for investigating
these disorders in populations with a high preva-
lence of consanguinity, as is evident from the
many recent studies that have identified causal
mutations.260–265
The effects of consanguinity and recessive var-
iants or heterozygosity levels on the risk of
complex phenotypes (diseases and quantitative
traits) are well established.266–268 Higher levels of
relative heterozygosity have been shown to be
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associated with lower blood pressure and total and
low-density lipoprotein (LDL) cholesterol by
measuring genome-wide heterozygosity.268 In
addition to quantitative traits, inbreeding has also
been found to be a significant positive predictor for
a number of late-onset complex diseases, such as
coronary heart disease, stroke, cancer and
asthma.266 These studies have strongly supported
the hypothesis that the genetics of complex pheno-
types include a component which corresponds to
recessively acting variants. The importance of
ROHs to complex phenotypes remains largely
unexplored; however, several studies have shown
significant differences in ROHs between cases and
controls in genome-wide investigations for schizo-
phrenia269 and late-onset Alzheimer’s disease.270
Success was also achieved for complex quantitative
traits such as height, where strong statistical evi-
dence for an association of a particular ROH with
height was obtained in a total sample size of
.10,000. The height of individuals with this
ROH was significantly higher (increased by
3.5 cm) than the individuals lacking the region.258
Cataloguing ROHs in human genomes and investi-
gating their associations with complex phenotypes
by building on existing GWAS data should be fruit-
ful areas for future research.
Beyond SNPs: CNVs
A new era of CNV discovery began when two
separate studies, published concurrently in 2004,
identified several hundred deletions and duplications
in the human genome.26,27 Such genetic abnormal-
ities had actually been documented decades before,
however, in clinical cytogenetics studies that found
them to be a cause of various genomic or cytoge-
netic disorders.271 The distinguishing feature of the
recent studies was that these CNVs were found to
be much more prevalent in the human genome than
previously expected. These changes in copy number
did not result in any clinical disorder or pathological
phenotype and were found in the genomes of
phenotypically normal individuals. As these submi-
croscopic (,5 Mb) deletions and duplications were
below the detection limit of traditional cytogenetics
tools such as fluorescence in situ hybridisation
(FISH), these recent discoveries were credited to the
use of whole-genome microarray technologies.272
Although these early whole-genome microarray
studies discovered several hundred new CNVs, it
was clear from the outset that that this would be a
gross underestimate of the true total. These studies
used ‘low-resolution’ microarrays such as represen-
tational oligonucleotide microarray analysis (ROMA)
containing 85,000 probes with a resolution of
approximately one probe per 35 kb26 or the bacterial
artificial chromosome–comparative genomic
hybridisation (BAC-CGH) array with a resolution of
approximately one probe per 1 Mb.27 Further, these
studies investigated a small sample size, which
limited the efficiency of detection of less common
CNVs. CNVs smaller than 50–100 kb would not
have been detected because their size was below the
resolution limit for these microarrays. Thus, both
the sample size and the resolution of the microarray
are critical factors that contribute to the discovery of
less common and/or smaller CNVs.
The contribution of CNVs as a major source of
genetic variation in human populations has become
appreciated despite the limitations of the microarrays.
The first comprehensive mapping of CNVs in 270
samples from the HapMap Phase I project identified
a total of 1,447 copy number variable regions, cov-
ering 360 Mb. These regions contained hundreds of
genes, disease loci, functional elements and segmen-
tal duplications.22 The limitations of ROMA and
the BAC-CGH arrays have been overcome in later
studies by the use of higher-resolution microarrays
and larger sample sizes comprising several hundred
samples.23,105,273–276 High-resolution tiling oligonu-
cleotide microarrays, comprising 42 million probes,
were used to generate a comprehensive map of
11,700 CNVs.105 Yim et al.275 screened CNVs in
3,578 healthy, unrelated Korean individuals, using
the Affymetrix SNP Array 5.0.
Other types of chromosomal rearrangement, par-
ticularly inversions and balanced translocations,
have received considerably less attention.277–279
Inversions and translocations are also known as
‘copy-neutral variations’ or ‘balanced chromosomal
rearrangements’, since they do not involve changes
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in copy number. These copy-neutral variations
have also been found to be associated with
disease.279 Collectively, these copy number and
copy-neutral variations are broadly classified as
‘structural variations’. As discussed, the genome-
wide mapping and detection of CNVs in different
populations has advanced considerably since 2004,
being driven mainly by microarray technologies
such as oligonucleotide-CGH and SNP microar-
rays. By contrast, the pace in identifying inversions
and translocations in the human genome has been
slower because more powerful and effective
methods were not available until the advent of
NGS technologies76 (Boxes 4 and 5).
The discovery of a 20 kb deletion located
immediately upstream of the immunity-related
GTPase family M gene (IRGM) underlying Crohn’s
disease, and the identification of a 45 kb deletion
that is in perfect LD with body mass index-
associated SNPs near the neuronal growth regulator
1 gene (NEGR1),287,288 together with other studies
reporting evidence for LD of CNVs with
GWAS-SNPs at r2. 0.5, suggest possible associ-
ations of CNVs with a variety of different human
complex diseases and traits.105 The genome-wide
study performed by the Wellcome Trust Case
Control Consortium (WTCCC) investigating the
association between 3,400 common CNVs and
eight complex diseases in 19,000 samples did not
yield any novel discoveries;111 however, rare CNVs
associated with various complex phenotypes have
been identified in studies of schizophrenia,250,289,290
epilepsy251 and severe early-onset obesity.252,253 The
studies on schizophrenia found that rare structural
variations that disrupt multiple genes in neurodeve-
lopmental pathways are over-represented in cases, as
compared with controls.250,289
High-throughput sequencing
technologies and their impact on
genomic studies
The advent of high-throughput sequencing tech-
nologies has initiated the ‘personal genome sequen-
cing’ era for both normal and cancer genomes, and
large-scale genome sequencing studies such as the
1000 Genomes Project and the International
Cancer Genome Consortium. The high-
throughput sequencing technologies also provide
new opportunities to study Mendelian disorders
through exome sequencing and WGS. Several
international projects have also been launched to
explore functional genomics.
High-throughput sequencing technologies
NGS technologies have only been on the market
since 2004, but have now largely replaced Sanger
sequencing technologies (owing to the
ultra-high-throughput production capacity of NGS
technologies, which is a thousand times greater than
that of traditional sequencing). One of the major
differences is the ability of next-generation sequen-
cers to simultaneously sequence millions of DNA
fragments; hence, they are also referred to as mas-
sively parallel sequencing technologies. This feature
has considerably increased the number of nucleotides
that can be sequenced per instrument run when
compared with Sanger sequencing. The sequencing
chemistry of NGS technologies, together with their
ultra-high-throughput production capacity, has also
reduced sequencing costs significantly, making
large-scale or WGS studies much more afford-
able.29–31 The sequencing technologies currently
available can be broadly grouped into NGS technol-
ogies such as the Roche 454 Genome Sequencer
FLX (GS FLX) System, Illumina Genome Analyzer
(GA) and HiSeq and Life Technologies Supported
Oligonucleotide Ligation Detection System
(SOLiD), and TGS (or single-molecule sequencing)
technologies such as the HeliScope Single Molecule
Sequencer (Helicos Biosciences).32
One of the more laborious steps in WGS using
the Sanger method was the in vivo amplification
step using bacterial cloning. This has now been
substituted by the in vitro amplification of millions
of DNA fragments by NGS technologies using
emulsion polymerase chain reaction (PCR) (Roche
GS FLX and Life Technologies SOLiD) or bridge
amplification on a solid surface (Illumina GA and
HiSeq). The sequencing approach for NGS
Human genetics and genomics a decade after the release of the draft sequence of the human genome REVIEW
# HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 6. 577–622 OCTOBER 2011 595
Box 4. Characterising structural variation by means of sequencing
The discovery of copy-neutral variations has been attributed to the development of the PEM method
and concurrent advances in NGS technologies. The PEM method has also contributed greatly to the
discovery of CNVs in the human genome.76,81,280 Further studies have also taken advantage of an
important feature of sequencing data generated by NGS technologies, where several hundred million
short sequence reads are produced per instrument run to detect CNVs based on the abundance or
density of the sequence reads aligned to the reference genome. This approach is known as
depth-of-coverage (DOC) and is similar to microarray-based methods, in that it is also unable to detect
copy-neutral variations.281
PEM
In the PEM method, a library of DNA fragments with a fixed insert size is prepared and both ends of
the DNA fragments are sequenced to generate ‘paired-end sequences’ (the sequences at both ends of
the DNA fragments). This sequence information is then aligned against the reference genome. The
underlying principle of PEM in detecting structural variations is reliance upon the discordance in insert
size and orientation of the paired-end sequences being aligned to the reference genome to infer
‘simple’ deletion, insertion and inversion. Thus, when paired-end sequences aligned to the reference
sequence display discordance from the expected insert size or distance, this is indicative of either a del-
etion or an insertion, whereas discordance in orientation suggests the presence of an inversion (ie
paired-end sequences are incorrectly oriented by comparison with the reference genome). Hence, the
paired-end sequences are usually classified as ‘concordant pairs’ or ‘discordant pairs’; only the discordant
pairs are informative for inferring structural variants. Other, more complex, rearrangements — such as
‘everted duplications’, ‘linked insertions’ and ‘hanging insertions’ — can also be detected.282
DOC
The DOC method utilises NGS data for CNV detection. This method is based on the DOC of the
sequence reads to infer deletions and duplications. The DOC method is made possible by the pro-
duction of several hundred million short sequence reads per instrument-run by NGS technologies. The
principle underlying the DOC approach is based on the assumption that the sequencing process is
uniform, so that the number of sequence reads mapping to a region follows a Poisson distribution. As
such, the number of sequence reads should be proportional to the number of times that a particular
region appears in the genome. Therefore, it is expected that a duplicated region will have more reads
aligned with it, with the converse being true for deletions.281,282 The assumption that the sequencing
process is uniform may not be valid, however, because of the sequencing bias of the NGS technologies,
which leads to certain regions of the genome being over- or under-sampled, resulting in spurious
signals.283 Despite their shortcomings, the PEM and DOC methods will continue to play a role in the
discovery of structural variations until de novo genome assembly becomes more feasible.
Application in cancer studies
Both PEM and DOC have also proven useful in dissecting somatically acquired rearrangements in
cancer genomes.87,284 Sequencing of both ends of the DNA fragments derived from the genomes of
two individuals with lung cancer was performed and 306 germline structural variations and 103
somatic rearrangements were identified to the single nucleotide level of resolution.87
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Box 5. International effort to characterise structural variants using PEM
Proof-of-concept studies
The PEM method for detecting structural variants was first demonstrated by Tuzun et al. by mapping
paired-end sequences data from a human fosmid DNA genomic library.285 The average insert size of a
fosmid library is approximately 40 kb. This study identified 297 structural variants (139 insertions, 102
deletions and 56 inversions); however, sequencing of fosmid clones by means of Sanger sequencing is
laborious and costly.285 These limitations have been overcome by NGS technologies which directly
sequence the paired-end or mate-pair libraries without the need for cloning steps.76 Both of these
studies applied the PEM approach to investigate structural variants in the same sample (NA15510) from
the International HapMap Project. Their library insert sizes differed, however, and this has enabled a
comparison of the sensitivity between these studies. Korbel et al.76 were able to confirm 41 per cent of
all deletion and inversion events detected by fosmid paired-end sequencing. Moreover, they identified
an additional 407 structural variants in NA15510 that previously had not been detected by fosmid
paired-end sequencing. This further suggests that several libraries with different insert sizes are needed
to increase the sensitivity of PEM.
Human Genome Structural Variation Working Group
In addition to individual studies, a large-scale effort is currently being undertaken by the Human
Genome Structural Variation Working Group comprehensively to map structural variants in phenotypi-
cally normal individuals using the PEM approach.79 More specifically, the objective is to characterise
the pattern of human structural variants at the nucleotide sequence level from a collection of 48 indi-
viduals of European, Asian and African ancestry. This project plans to make fosmid clone libraries of
approximately 40 kb insert size from the genomic DNA of 48 unrelated females. These samples were
already genotyped by the HapMap Project. A larger insert size of approximately 150 kb prepared from
BAC clone libraries will also be constructed from 14 unrelated HapMap males. This will aim to
provide sequence information on structural variants that are too large to be included in the fosmid
libraries, such as those associated with segmental duplications. As such, both the fosmid and BAC
libraries will ensure the comprehensive capture of structural variants of varying sizes across the human
genome.
Structural variation is biased toward complex duplicated and repetitive regions. Hence, developing
clone libraries for a modest number of human genomes should serve as a valuable resource for char-
acterising complex and difficult-to-assay regions of genome structural variation. Since the underlying
clones can be retrieved, the complete sequence context of the discovered structural variant can also
be obtained.79 This is crucial for precise breakpoint delineation of structural variation, which is then
important for understanding the mutational mechanisms responsible for human genome structural
variation. A total of 1,695 structural variants were discovered with fosmid libraries derived from nine
individuals. The study also showed that 50 per cent were seen in more than one individual and that
nearly half lay outside regions of the genome previously described as structurally variant, indicating
novel discoveries. More importantly, 525 new insertion sequences (that are not present in the human
reference genome) were discovered and many of these were found to be variable in copy number
between individuals.86 This is important because it suggests that structural variants or CNVs could
have gone undetected as part of the ‘missing sequences’ in the human reference genome. Complete
sequencing of 261 structural variants provided insights into the different mutational processes that
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technologies broadly can be divided into: (1)
sequencing-by-synthesis mediated by DNA poly-
merase (ie pyrosequencing for Roche GS FLX and
sequencing by reversible terminator chemistry for
the Illumina sequencing platform); and (2)
sequencing-by-synthesis mediated by DNA ligase
for Life Technologies SOLiD.29–31
Whole-genome resequencing can now be
accomplished relatively rapidly because of the avail-
ability of the HGP template for alignment of the
billions of short sequence reads produced by next-
generation sequencers. This is necessary because
the NGS technologies are characterised by short
sequence read lengths of approximately 50–125 bp
for both Illumina and Life Technologies sequencing
platforms.29–31 This feature makes de novo sequen-
cing, or the assembly of billions of short sequence
reads into large contigs challenging — especially
for large and complex genomes like the human
genome.291 A longer read length is key to obtain-
ing larger contigs with fewer gaps between them
during the assembly steps. Although the latest
improvements in sequencing chemistry and systems
allow the Roche GS FLX to achieve a sequence
read length of 500 bp on average, this is still mark-
edly lower than the 800 bp to 1 kb length achieved
by Sanger sequencing (http://www.454.com/).292
In addition to a short read length, NGS technol-
ogies have higher sequence error rates, although
this gradually has been improving.293
A relatively new addition in the NGS market
is the Ion Torrent Personal Genome Machine
(PGM) produced by Life Technologies
(http://www.iontorrent.com/). The earlier NGS
technologies relied on emission of either fluor-
escent (Illumina and Life Technologies SOLiD
sequencing platforms) or chemiluminescent
(Roche GS FLX) light to detect and distinguish
the nucleotides incorporated during sequencing.
However, the Ion Torrent PGM uses proprietary
semiconductor sensors to perform direct real-time
measurement of the hydrogen ions released upon
incorporation of nucleotides during sequencing.
Several ion semiconductor sequencing chips will be
available, with throughputs ranging from .10 Mb
to .1 gigabase (Gb) per instrument run, but these
are many-fold lower than the several hundred Gb
of sequencing data generated by the latest Illumina
HiSeq and Life Technologies SOLiD machines.
The Ion Torrent PGM is therefore more suitable
for smaller-scale targeted sequencing.
The first TGS instrument — the Heliscope
Single Molecule Sequencer — is now commer-
cially marketed by Helicos Biosciences. The
Heliscope Single Molecule Sequencer or true
single-molecule sequencing (tSMS) is vaguely
classified as a TGS technology because it has fea-
tures of both NGS and TGS technologies. It is
considered to be a TGS platform because of its
ability to perform single DNA molecule sequen-
cing without the need for whole-genome amplifi-
cation but the sequencing is still based on ‘cyclic
sequencing’ (repeated cycles of sequencing) com-
prising several steps, such as flow of
fluorescent-labelled nucleotides and reagents,
nucleotides incorporation, washing and imaging
have shaped the human genome. This study therefore provided the first high-resolution sequence
map of human structural variation.86 A subsequent study then expanded the Human Genome
Structural Variation clone resource by including capillary end sequencing of 4.1 million additional
fosmid clones from eight additional human genomes. The combined set includes 13.8 million clones
derived from the genomes of six YRI, five Centre d’Etude du Polymorphisme Humain (CEPH)
Europeans, three JPT, two CHB and one individual of unknown ancestry.286 This study characterised
the complete sequence of 1,054 large structural variants and analysed their breakpoint junctions to
infer their potential mechanisms of origin. Three mechanisms were found to account for the bulk
of germline structural variation: microhomology-mediated processes involving short (2–20 bp)
stretches of sequence (28 per cent), non-allelic homologous recombination (22 per cent) and L1
retrotransposition (19 per cent).
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steps, in each cycle.32 Therefore, one of the major
distinctions between NGS and TGS is that TGS
does not require whole-genome amplification steps.
Numerous other TGS technologies, such as
SMRT sequencing, are on the horizon and
will soon be marketed commercially,294 whereas
others — such as nanopore sequencing — may
take several years to become a mature technol-
ogy.34,35 SMRT sequencing is performed by
synthesising complementary strands of the single
DNA molecules by DNA polymerase through
incorporation of four different fluorescent colour-
labelled nucleotides. The incorporation of each
nucleotide into the synthesising DNA strands is
monitored in real time by visualisation of ‘pulses’ of
coloured light emitted from each zero-mode wave-
guide. Each waveguide corresponds to a single mol-
ecule of DNA fragment and the incorporation of
nucleotides is distinguished by emission of four
different colours of light. Similarly, nanopore
sequencing requires no cyclic sequencing steps.32
By comparison, companies such as Complete
Genomics (Mountain View, CA) provide a sequen-
cing service, rather than selling their sequencing
machines to end-users. The sequencing platform
achieves efficient imaging and low reagent con-
sumption with combinatorial probe anchor ligation
chemistry independently to assay each base from
patterned nanoarrays of self-assembling DNA nano-
balls.44 As TGS is characterised by single DNA
molecule sequencing, it has the potential further to
increase the number of sequence reads or through-
put per instrument run above their current
capacity.
Whole-genome (re)sequencing
NGS and TGS technologies have now made poss-
ible the sequencing of the entire human genome
within a few days. The first human WGS study
using a next-generation sequencer was completed
in 2008;46 this marked the beginning of a new era
in personalised genome sequencing. To date, more
than 20 WGS studies have been completed using
NGS and TGS technologies.45 The number of
genomes being sequenced is expected to increase
in the coming years, as sequencing technologies
and analytical and bioinformatics tools become
more advanced and affordable.295 The reference
genome sequence from the HGP is needed for
alignments of the large amount of sequence reads
produced by the high-throughput sequencers.
Clearly, these studies do not involve the de novo
assembly of human genome sequences, but rather
constitute genome resequencing studies.
The first human diploid genome sequence —
Craig Venter’s genome — appeared in 2007 and
was sequenced using the Sanger sequencing
method.68 A year later, the genome of James
Watson, who discovered the double-helical struc-
ture of the DNA molecule half a century ago, was
also sequenced.46 In contrast to Venter’s genome,
Watson’s genome was sequenced using NGS tech-
nologies. A number of additional human genomes
have now also been fully sequenced. For example, a
single Caucasian/European;92 a single African (ie
NA18507 from the HapMap project, sequenced
using two different NGS technologies);42,296 two
Koreans;297,298 a single Han Chinese;43 a single
Japanese;299 a single Irish individual300 and a single
Gujarati Indian301 have been sequenced.
Two whole genomes of the indigenous hunter-
gatherer peoples of southern Africa (Khoisan and
Bantu) have also been sequenced, together with the
protein-coding regions from an additional three
hunter-gatherers from the Kalahari. This study has
been important for understanding human diversity,
as these genomes represent the oldest known
lineage of modern humans. A better understanding
of genomic differences between the hunter-
gatherers and others may help to pinpoint genetic
adaptations to an agricultural lifestyle.302 In
addition, the genome of an extinct Palaeo-Eskimo
(4,000-years old)108 and a Neanderthal
genome107 have been sequenced. The sequencing
work of most of these individual genomes was
accomplished using NGS technologies.
These WGS studies have identified several
hundred thousand new SNPs that had not been
previously catalogued in the dbSNP database. For
example, Bentley et al. (2008)42 found about one
million new SNPs in the African genome
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(NA18507), and several hundred thousand new
SNPs for other genomes. Most of the common
SNPs in human populations have already been cap-
tured; thus, the new SNPs identified in these
studies are probably representative of those from the
lower-frequency spectrum. Data on population fre-
quencies of the new SNPs are not available, since
they were derived from individual genome-
sequencing studies; however, these data should be
available upon completion of the 1000 Genomes
Project. In addition to SNPs, several hundred thou-
sand short indels and several thousand structural
variants have also been identified.
Schuster et al. characterised the extent of whole-
genome and exome diversity among five individuals
(two whole genomes and three exomes were
sequenced) and identified 1.3 million novel DNA
differences genome-wide.302 Interestingly, in terms
of nucleotide substitutions, the Bushmen would
appear to be genetically more different from each
other than Europeans and Asians are to each other.
This is consistent with the view that the genetic
diversity between African individuals is greater than
between individuals from other ethnogeographic
origins.302 A total of 353,151 high-confidence
SNPs were identified in the genome of the extinct
Palaeo-Eskimo.108 By comparing the high-
confidence SNPs in this extinct human genome
with contemporary populations to identify the
populations most closely related to this individual,
this study provided evidence for a migration from
Siberia into the New World some 5,500 years ago.
Comparisons of the Neanderthal genome with the
genomes of five extant humans from different parts
of the world identified a number of genomic
regions that may have been affected by positive
selection in ancestral modern humans, regions that
include genes involved in metabolism and in cogni-
tive and skeletal development.107
The WGS studies also identified a portion of the
sequence reads that could not be mapped to the
NCBI human reference genome, indicating that
some sequences are ‘missing’ from the reference
genome. For example, Wheeler et al. found that
1.5 million reads (approximately 1.4 per cent of the
total sequence data) did not map to the reference
genome.46 These ‘unmappable’ sequence reads
were then assembled into 170,000 contigs span-
ning 48 Mb. Even after the removal of contigs that
were ,100 bp in size, there were still 110,000
contigs spanning 29 Mb. This concurs with the
estimated 25 Mb of euchromatic sequence that is
absent from the reference genome. More recent
studies using sequencing data have also identified
new sequences that are absent in the human refer-
ence genome.303,304
1000 Genomes Project
The 1000 Genomes Project was initiated in 2008
with the aim of sequencing the genomes of at least
1,000 individuals from different populations around
the world (http://www.1000genomes.org/). The
main aim of this international collaborative project
has been to provide a comprehensive map of
human genetic variation for future disease associ-
ation studies and population genetics. As with the
HapMap project, the data from this project also will
be made available publicly.
Owing to the ease of high-throughput genotyp-
ing technologies, SNPs have been widely used as
genetic markers in GWASs to search for disease var-
iants. Evidence has been accumulating to suggest
that (common) SNPs alone are unlikely to account
for all the heritable risk of complex disease,
however.5 Concurrently, the amount of data sup-
porting associations of CNVs with complex dis-
eases has been growing.305 Similarly, the
importance of rare variants in complex diseases is
also increasingly being recognised.306,307 This indi-
cates that future disease association studies need to
interrogate non-SNP and rare genetic variants,
requiring a comprehensive catalogue of human
genetic variants. Common SNPs have been well
documented in the dbSNP, but rarer (or lower fre-
quency) SNPs are still under-represented in the
database and information on indels and structural
variations is still incomplete.
The completion of the pilot phase of the 1000
Genomes Project identified approximately 15
million SNPs, one million short indels and 20,000
structural variations, most of which were previously
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unreported.102 In addition, the location, allele fre-
quency and local haplotype structure of these
genetic variants were described. The sequencing
data also enabled characterisation of CNVs within
heavily duplicated and near-identical regions.308
Recently, a map of CNVs was constructed based
on WGS data from 185 human genomes in the
pilot phase of the project; this encompasses 22,025
deletions and 6,000 additional structural variations,
including insertions and tandem duplications. More
importantly, approximately half of the structural
variations were mapped to single nucleotide resol-
ution, thereby facilitating analysis of their origin
and functional impact.112 Precision in terms of the
breakpoint delineation of structural variations is a
prerequisite to obtain insights into their underlying
mutational mechanisms.286 The nucleotide resol-
ution analysis of the breakpoints was hampered by
the low resolution of the microarrays used in pre-
vious studies.
A recent study also identified approximately two
million small indels, ranging from 1 bp to
10,000 bp in length, in the genomes of 79 humans.
Interestingly, approximately half of these variants (ie
819,363 small indels) mapped to human genes.
These small indels were frequently found in the
coding exons of these genes, and several lines of
evidence indicate that such variation is a major
determinant of human biological diversity.309 This
study also found that many of the small indels had
high levels of LD with both HapMap-SNPs and
GWAS-SNPs, suggesting that a proportion of these
indels have already been interrogated indirectly for
their associations with complex phenotypes in
GWASs through LD with the SNPs as surrogate
markers. This also indicates that, in addition to
SNPs and larger CNVs, small indel variation is
likely to be a key factor underlying the genetics of
human complex diseases and traits.
By comparison with WGS, which relies on a
reference genome for aligning the sequence reads,
de novo genome assembly will enable the more
thorough and comprehensive detection of various
genetic variations in the human genome ranging
from single nucleotide variants and small indels, to
large structural variations. Currently, de novo
genome assembly is challenging and less practical
because of the short sequence reads generated by
NGS technologies, especially the Illumina and Life
Technologies sequencing platforms. Recent studies
have attempted to perform de novo human genome
assembly using short sequence reads, with limited
success.291,310,311 One such study showed that de
novo assemblies were 16.2 per cent shorter than the
reference genome, with thousands of coding exons
being completely absent.312 De novo genome assem-
bly and haplotype phasing will eventually become
more feasible with longer sequence read lengths of
up to tens of kb being generated by future sequen-
cing technologies.33
Cancer genome sequencing and somatic
mutations
Cancers differ from other complex diseases in several
aspects. The involvement of somatic mutations in
cancer initiation and progression, in addition to
germline variations, is well recognised. Sporadic
cancer is considered to be an ‘acquired disease’
caused by the accumulation of somatic mutations in
the genome of the original cancer cell type over the
lifespan of a patient. Direct sequencing of the
cancer genome, and comparison with the genome
sequence from constitutional DNA from the same
individual as a reference, is required for the proper
assessment of somatic mutations.313,314
Recent advances in the understanding of the
somatic mutational profile of cancer genomes have
been driven by NGS technologies, which have
enabled numerous whole cancer genomes to be
sequenced for the first time.47–49 Nevertheless,
many large-scale targeted resequencing studies of
collections of cancer-relevant candidate genes, gene
families or the RefSeq genes also have been per-
formed previously using traditional PCR isolation
and Sanger sequencing methods. The scale of these
targeted studies previously has been limited by the
lack of high-throughput sequence capture and
sequencing methods.315,316 By contrast, sequencing
of the entire collection of exons in acute monocy-
tic leukaemia was completed without PCR iso-
lation and Sanger sequencing methods.317
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Although somatic mutations have been found in
many genes, only a few genes have been found to
be frequently mutated across the tumour samples
screened (ie mutated in a significant proportion of
cancer samples). These genes have been referred to
as ‘mountains’ — as opposed to the ‘hills’, which
correspond to genes that are infrequently mutated
or mutated at low frequency.316,318–320 For
example, the gene encoding V-erb-a erythroblastic
leukaemia viral oncogene homolog 4 (avian)
(ERBB4) was found to be the most highly mutated
gene in melanoma and hence may be considered to
be a ‘mountain’; a considerable proportion of
samples (19 per cent) were found to have somatic
mutations in this gene, with some samples contain-
ing more than one mutation. The role of ERBB4
was also supported by extensive functional studies
showing that various missense mutations increased
kinase activity and transformation ability, and the
demonstration of reduced cell growth after knock-
down of the gene in melanoma cells expressing
mutant ERBB4.320 Targeted cancer genome
sequencing has demonstrated the potential to ident-
ify potential therapeutic targets for melanoma.
Despite cost constraints, the number of WGS
studies performed on different cancers has been
increasing47–49 since the milestone first study that
sequenced the cancer genome of an AML
patient;82 however, these WGS studies have gener-
ally sequenced only a few samples.321–323 The
ability of WGS to detect somatic mutations in
abundance requires us to be able to identify the
‘driver’ mutations from among the myriad ‘passen-
ger’ mutations. It has been predicted that approxi-
mately ten functional driver mutations are required
to cause most cancers, yet up to tens of thousands
of mutations may be identified in an analysis of a
cancer genome.313,314 Effective methods for identi-
fying driver mutations in cancer genomes are not
well developed, and the criteria for distinguishing
driver mutations are not well defined. In addition,
the set of driver mutations can be very different for
different cancer types.
Although frequently mutated genes and recur-
rent mutations are of particular interest,324 all of
the current studies have interrogated only one or a
few cancer genomes. Thus, these studies are unable
to distinguish ‘mountains’ from ‘hills’, and recur-
rent mutations from other mutations that occur
only once in the samples. Therefore, testing a
subset of somatic mutations identified in the cancer
genome in a larger number of cancer samples is
required to identify this subset of genes or
mutations325 before the application of WGS in
larger samples can be regarded as not only techni-
cally feasible, but also affordable (Box 6).
At present, somatic mutations in non-coding
regions have received relatively scant attention and
should be given more importance, since pervasive
transcription beyond the protein-coding regions
has now been demonstrated,165,333,334 suggesting a
regulatory role for the non-coding regions. These
somatic mutations, and possibly driver mutations in
the non-coding regions, can only be revealed by
sequencing the whole cancer genome, as opposed
to a targeted approach.
Revisiting Mendelian disorders
Mendelian or monogenic disorders make up
approximately 7,000 known or suspected disorders
and contribute significantly to the disease burden
in society.335–338 Over the past two decades, much
progress has been made in identifying the causal
mutations and candidate genes for Mendelian dis-
orders through mainly traditional linkage studies.339
Currently, causal mutations for .4,000 Mendelian
disorders have been identified.99 Indeed, a total
of 112,864 different disease-causing and
disease-associated mutations in 4,078 human genes
are currently (as of May 2011) catalogued in the
HGMD (http://www.hgmd.org/) (Box 7).
Although classical linkage studies have been the
main tool for elucidating the genetics of Mendelian
disorders, not all of these disorders are amenable to
this study design. Homozygosity mapping is a
more powerful and effective approach to studying
recessive disorders in consanguineous families. For
those disorders that are not amenable to these two
conventional approaches, their causal mutations
remain elusive. These disorders include: (a) extre-
mely rare Mendelian disorders where only a small
REVIEW Naidoo et al.
602 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 6. 577–622 OCTOBER 2011
Box 6. Challenges in cancer genome sequencing
Several major challenges at the forefront of cancer genome sequencing studies are outlined and dis-
cussed. The first relates to the collection of ‘high-quality’ samples of cancer cells or tissues for DNA
extraction for sequencing.48,49 Primary cancer tissues are usually contaminated by other normal cells
that hamper our ability to detect somatic mutations in cancer genomes. The contamination with (or
mixture of ) DNA from non-cancerous cells is particularly problematic, and a higher depth of sequen-
cing coverage will be required to detect somatic mutations in ‘mixed DNA’, increasing the cost of
sequencing. For example, Ding et al. studied 188 primary lung adenocarcinoma samples, each contain-
ing a minimum of 70 per cent tumour cells independently determined by pathologists.326 Single-cell
sequencing is now emerging as a promising approach to resolving cancer tissue heterogeneity or mixed
populations of cells, however, because it is potentially able to resolve genetic and/or cellular heterogen-
eity among the cancer cells. This single-cell sequencing approach was applied to investigate tumour
population structure and evolution in two cases of human breast cancer. Analysis of 100 single cells
from a polygenomic tumour revealed three distinct clonal subpopulations that probably represent
sequential clonal expansions. Analysis of 100 single cells from a monogenomic primary tumour and its
liver metastasis indicated that a single clonal expansion formed the primary tumour and seeded the
metastasis.113
The second most important challenge is accurately to identify different types of somatic mutations in
the cancer genome. NGS technologies are characterised by shorter sequence read lengths and higher
sequencing error rates, by comparison with Sanger sequencing.295 Data quality could be adversely
affected if these sequencing errors are not properly filtered out.
Thirdly, the cost of whole-genome resequencing is still prohibitively expensive when it is to be
applied to hundreds of samples. Furthermore, there are also significant bioinformatics and analytical
challenges to processing and analysing huge amounts of sequencing data. These two constraints cur-
rently restrict whole-genome resequencing studies to studies of only a few cancer genomes. This in
itself becomes a major barrier to identifying recurrent mutations (which are more likely to be function-
ally important) and driver mutations. Although the current approach to identifying recurrent mutations
is to select a subset of somatic mutations detected in cancer genomes and then to test them in a larger
study,325 this approach cannot be used to screen for all mutations, resulting in many recurrent mutations
remaining undetected. For example, a total of 64 mutations were detected in protein-coding genes,
regulatory RNAs and highly conserved non-coding regions in the AML genome, but only four of
these mutations were subsequently found in additional samples when tested for in more than 180 AML
patients. By contrast, targeted resequencing in large sample sizes is able to identify recurrent mutations.
This targeted approach focuses only on certain genes, however, and, as a consequence, those recurrent
mutations located outside the targeted regions remain undetected. In addition to identifying recurrent
mutations, a large sample size is also needed to distinguish ‘mountains’ from ‘hills’.
Although the findings from targeted,315,316,320,326,327 exome317,328,329 and whole-genome resequen-
cing82,321–323,330–332 studies have increasingly provided new insights into cancer genomes, the greatest
challenge for cancer genome sequencing lies in discerning driver mutations from the multitude of
other (passenger) mutations. Effective methods for identifying driver mutations in cancer genomes are
not yet well developed. In addition, driver mutations may differ between cancer types.
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number of cases are available; (b) unrelated cases
from different families; and (c) sporadic cases due
to de novo mutations. Exome sequencing now offers
new opportunities to study extremely rare disorders
and sporadic cases caused by de novo mutations,
such as Kabuki syndrome and Schinzel–Giedion
syndrome.14,340
High-throughput sequence capture methods are
able to isolate the universe of exons (the ‘exome’) in
a more efficient and cost-effective way than tra-
ditional PCR-based methods. These methods are
commercially marketed — for example, the
NimbleGen Sequence Capture technology
(NimbleGen, Madison, WI: http://www.nimblegen.
com/) and the Agilent SureSelect Target Enrichment
technology (Agilent; Santa Clara, CA: http://www.
home.agilent.com). They allow researchers to target
custom genomic regions of interest in the human
genome of up to tens of Mb in length, and also
enable isolation of the exome in a single experiment.
This development, coupled with the high-
throughput sequencing data produced by NGS tech-
nologies, ensures an adequate depth of sequencing
coverage accurately to detect the genetic variations in
the exome or targeted regions.295,341,342
Causal mutations have been identified for a
number of previously unexplained rare disorders,
such as Miller syndrome,13 Sensenbrenner syn-
drome,343 Perrault syndrome344 and Fowler syn-
drome.345 Exome sequencing is also a useful tool
for diagnostic application and is anticipated to be
used increasingly in molecular diagnosis.90,346–348
The genetic diagnosis of congenital chloride diar-
rhoea in a patient with suspected Bartter syndrome
was made through exome sequencing, which
revealed a homozygous missense variant in the
solute carrier family 26, member 3 gene
(SLC26A3).90 The position of this variant is com-
pletely conserved from invertebrates to humans.
The diagnostic application was further illustrated by
Lupski et al. through WGS of a proband with
Charcot–Marie–Tooth disease.16 One missense
variant and one nonsense variant were detected in
SH3TC2, and all affected individuals in the family
of the proband were found to be compound het-
erozygotes for these variants.
Studying Mendelian disorders can, paradoxically,
reveal genes for complex diseases and traits. For
example, numerous GWAS-identified common
SNPs which are associated with triglyceride, high-
density lipoprotein (HDL) cholesterol and LDL
cholesterol levels were also found in the candidate
genes causing the monogenic form of these lipid
metabolism disorders.349,350 The discovery of causal
Box 7. Human Gene Mutation Database and the ‘human mutome’
As the number of disease-causing or disease-associated germline mutations or variants increases, proper
cataloguing is critically important. In this regard, the HGMD represents an attempt to collate all
known (published) gene lesions responsible for human inherited disease.
Disease-causing or disease-associated germline mutations/variants collated in the HGMD now
exceed 110,000 in .4,000 different nuclear genes. Newly described human gene mutations are cur-
rently being reported at a rate of 10,000 per annum, with 300 new ‘inherited disease genes’ being
recognised every year. The HGMD has provided useful insights into the ‘human mutome’ (ie disease-
causing or disease-associated germline mutations/variants in the entire human genome).99,100 For a
variety of reasons, however, this figure is likely to represent only a small proportion of the clinically rel-
evant genetic variants present in the human genome. Those disease-causing or disease-associated var-
iants that are located outside the gene-coding regions are likely to have been overlooked often as a
direct consequence either of focusing exclusively on screening the protein-coding sequence or of the
inherent limitations of the mutation detection techniques used. Such considerations are important for
improving mutation screening strategies, as well as for facilitating the interpretation of findings from
GWASs, exome sequencing and WGS.
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mutations in the disease genes responsible for
Mendelian disorders should help in acquiring an
understanding of the underlying pathophysiology.
For example, the identification of causal mutations
in the gene encoding dihydroorotate dehydrogenase
(DHODH) for Miller syndrome has provided new
insights into the role of pyrimidine metabolism in
craniofacial and limb development.13 The potential
discovery of new drug targets through study of the
genetics of Mendelian disorders should also be
emphasised. Thus, statins, the most commonly
used drugs to lower cholesterol levels by inhibiting
the enzyme 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) reductase, were discovered by study-
ing familial hypercholesterolaemia.351
Currently, the return to Mendelian disorder
research has been mainly due to the ‘attraction’ of
the exome sequencing approach, coupled with the
disappointment engendered by GWAS results that
have served to explain only a small fraction of the
heritability of complex diseases and traits.
Nevertheless, studying complex diseases should not
be abandoned, as GWASs have also revealed new
biological insights, such as unravelling the autop-
hagy and interleukin (IL)-23 receptor pathways for
Crohn’s disease.352–354 The knowledge gained from
studying Mendelian disorders and complex diseases
will eventually complement each other and come
together synergistically to enhance our understand-
ing of genotype–phenotype relationships.
New efforts to identify further causal mutations
underlying Mendelian disorders include a recent
initiative by the National Human Genome
Research Institute (USA) to establish ‘A Center for
Mendelian Disorders’ whose mission will be to
take on the sequencing of Mendelian disorders.
This centre will be expected to explain the mol-
ecular basis of 40–50 disorders per year (NHGRI
Large-Scale Sequencing Program May 2010,
http://www.genome.gov/).
Sequencing-based approaches to the study of
functional genomics
The NGS technologies, since their introduction in
2004, have been increasingly applied in studies of
protein–DNA interactions and histone modifi-
cations (ChIP-Seq), transcriptomic profiling of
mRNAs and non-coding RNAs (RNA-Seq), and
bisulphite sequencing of DNA methylation
(Methyl-Seq).39–41
ChIP-Seq
Previous studies of protein–DNA interactions —
such as the identification of transcription factor
binding sites — have relied on several low-
throughput methods and have been focused on a
few specific genomic regions. In the era of micro-
arrays, the genome-wide studies of protein–DNA
interactions and histone modifications were per-
formed using a method known as ChIP-chip.355
Undeniably, microarray development has enabled
interrogation on a genome-wide scale but the
detection of the immunoprecipitated DNA
sequences is still dependent upon the availability of
probes to capture them. Although the development
of high-density tiling arrays,356 where oligonucleo-
tide probes are placed in high density throughout
the whole genome, has improved the sensitivity of
the ChIP-chip, the cost for such tiling arrays is
expensive, especially for large genomes like the
human genome.357 By contrast, for ChIP-Seq, the
immunoprecipitated DNA sequences are not hybri-
dised on microarrays (thereby avoiding the pro-
blems inherent in probe hybridisation experiments)
but instead are directly sequenced to detect their
presence and measure their abundance. This allows
detection of all the DNA fragments or sequences
that are immunoprecipitated without any bias in
relation to probe selection.357 This is a key advan-
tage of ChIP-Seq over microarrays.
ChIP-Seq or chromatin immunoprecipitation
with the paired-end ditag sequencing (ChIP-PET)
methods have led to major advances in the
genome-wide mapping of binding sites for tran-
scription factors (eg p53 transcription factor
binding sites),358 and for DNA binding proteins
such as neurone restrictive silencer factor (NRSF)
and signal transducer and activator of transcription
(STAT1).77,359 Studies of histone modifications
have also been revolutionised by means of
ChIP-Seq methodology;78 this has expanded our
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knowledge of how this epigenetic mechanism regu-
lates gene expression in the human genome.
ChIP-Seq has made an important contribution to
the studies of protein–DNA interactions and
histone modifications.360,361
RNA-Seq
Studies of gene expression are important because
they constitute immediate molecular traits that are
directly affected by variation in DNA sequences
and epigenetics. The term ‘gene expression’ usually
refers to the expression of protein-coding genes.
Previous studies were focused on mRNA
expression, as mRNAs serve as the templates for
protein synthesis; however, this perception changed
after the completion of the pilot phase of the
ENCODE project. This project and other studies
revealed ‘pervasive transcription’ in the human
genome.165,333,334 Previously it had been thought
that only the protein-coding regions or sequences
(ie genes) would undergo transcription followed by
translation; however, accumulating data are compa-
tible with the view that transcription also occurs in
non-protein-coding regions, indicating the impor-
tance of studying non-coding RNAs.
The advent of NGS technologies has spawned
new approaches to exploring the transcriptome (eg
RNA-Seq).362,363 This method allows the study of
the expression of mRNAs and non-coding RNAs,
and is also able to detect and identify new tran-
scripts (coding and non-coding) that have not
been formally annotated. The applications of
sequencing-based approaches in transcriptomic
studies have included genome annotation and the
discovery of new transcripts,364 the investigation of
the alternative splicing patterns,84,365 detection of
gene fusions in cancer366 and allele-specific
expression analysis,367 as well as the discovery and
measurement of non-coding RNA expression.
Methyl-Seq
Substantial progress has also been achieved in the
context of DNA methylation analysis with the
advent of NGS technologies allowing the determi-
nation of the DNA methylome at a single-base res-
olution.96,368–371 The ‘gold standard’ for the
detection of DNA methylation (or cytosine
methylation) is sodium bisulphite conversion of
DNA followed by sequencing. The sodium bisul-
phite treatment will convert the unmethylated
cytosine to uracil (subsequently read as thymine
during sequencing), whereas methylated cytosine
remains unchanged. One of the limitations of this
method, however, is that it cannot distinguish
between 5-methycytosine and 5-hydroxy-
methylcytosine. The importance of studying
5-hydroxymethylcytosine for its biological roles
will become clearer when more powerful methods
to distinguish them become available.372 The
SMRT sequencer produced by Pacific Biosciences
holds out great promise directly to sequence (and
distinguish) 5-methycytosine and 5-
hydroxymethylcytosine.373 Nanopore sequencing
technologies have also demonstrated the ability to
directly detect methylated cytosines.35 The revolu-
tion in sequencing approaches to exploring func-
tional genomics in the human genome has also led
to the initiation of several international projects
(Box 8).
Personalised genomic medicine
The translation of genomic information to the clini-
cal setting has shown great promise. In the field of
pharmacogenetics, the US Food and Drug
Administration (FDA) has approved genotyping tests
for the screening of genetic variants in candidate
genes that influence the responses and adverse effects
of several commonly used anticancer drugs (eg the
genes encoding thiopurine S-methyltransferase
[TPMT] and UDP-glucuronosyltransferase 1A1
[UGT1A1] for thiopurine drugs and irrinotecan,
respectively). Pharmacogenetic information is
important to guide the optimal dose prescription.384
Similarly, the FDA has also approved genotyping
tests for two genes (CYP2C9 and the vitamin K
epoxide reductase complex, subunit 1 gene
[VKORC1]) in the prescription of warfarin, a drug
of low therapeutic index.385
The over-expression status of human epidermal
growth factor receptor 2 (HER-2) receptors in
breast cancer patients is clinically informative in
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Box 8. International projects that are exploring functional genomics
The advent of NGS and TGS will facilitate the undertaking of several international projects (http://
commonfund.nih.gov/). These large-scale projects would not have been technically feasible without
NGS and TGS technologies, which have potentiated sequencing-based approaches in studying func-
tional genomics. These projects will contribute significantly to functional genomics.
The NIH Roadmap Epigenomics Program
The NIH Roadmap Epigenomics Program aims to generate new research tools, technologies, datasets
and infrastructure to accelerate our understanding of the role of epigenetics.374 This will improve our
understanding of instances of transcriptional regulation that are not dependent on the DNA sequence.
This will be important in understanding diseases attributed to epigenetic aberrations involving DNA
methylation or histone modifications.375 For example, many cancers are commonly associated with
epigenetic aberrations.376
The Genotype–Tissue Expression (GTeX) Project
Transcriptional regulation is modulated not only by epigenetics, but also by genetic variation in the
DNA sequence. Therefore, the GTeX Project aims to study human gene expression and regulation in
multiple tissues, providing valuable insights into the mechanisms of gene regulation and, in the future,
its disease-relevant aberrations. Genetic variation between individuals will be examined for a correlation
with differences in gene expression level. Major advances have been made in studies of eQTL through
the use of high-throughput genotyping and sequencing technologies.377–381 For example,
Montgomery et al. sequenced the mRNA fraction of the transcriptome in 60 HapMap individuals of
European descent and integrated the data with SNP information from the HapMap Phase III project,
an undertaking which led to discoveries of novel eQTLs and sequence variants responsible for alterna-
tive splicing.380
The Human Microbiome Project
The Human Microbiome Project aims to characterise the microbial communities found at several
different sites in the human body, such as oral cavities, skin, gastrointestinal tract and the urogenital
tract. This project is important in providing insights into the roles of these microbes in human health
and disease.382 The first metagenomic sequencing of gut microbes was accomplished using NGS tech-
nologies.103 A human gut microbial gene catalogue was established by characterisation of 3.3 million
non-redundant microbial genes derived from faecal samples from 124 European individuals. This
research is important in gaining better understanding of the influence of gut microbes on human
health and disease.103
The International Cancer Genome Consortium
New developments have also occurred in cancer genomics, where the International Cancer Genome
Consortium aims to obtain a comprehensive description of genomic, transcriptomic and epigenomic
changes in 50 different tumour types and subtypes.110 This is in accordance with the notion of integra-
tive analyses incorporating multiple sources of genomics data.383 This project will be important in dis-
secting the somatic genetic heterogeneity, a general hallmark of cancer, through studying various
tumour types and subtypes.
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deciding whether a given patient would benefit
from trastuzumab treatment. Similarly, the deletion
of CYP2D6 predicts whether a patient would
benefit from tamoxifen treatment, as this prodrug
requires bioactivation into its active metabolite, 4-
hydroxytamoxifen, which is catalysed by the
CYP2D6 enzyme. Thus, breast cancer patients
who would not benefit from trastuzumab and
tamoxifen treatments should be prescribed alterna-
tive drugs, such as aromatase inhibitors. In terms of
prognosis, breast cancer prognostic gene expression
arrays such as MammaPrint and Oncotype DX are
informative and relevant to clinical management, as
they help to determine which patients should
receive adjuvant therapy after surgery.386–388 These
examples highlight the potential clinical utility of
genomic information in prescribing and optimising
treatments.
Genomics information has also been used to
develop molecular-targeted cancer therapies. The
discovery of the breakpoint cluster region–c-abl
oncogene 1 nav-receptor tyrosine kinase (BCR–
ABL) genomic translocation ultimately led to the
development of a molecular-targeted drug as a
treatment for chronic myeloid leukaemia (CML),
namely imatinib — a tyrosine kinase inhibitor tar-
geting the tyrosine kinase domain of the fusion
protein.389 The identification of somatic mutations
in the epidermal growth factor receptor (EGFR) in
non-small-cell lung cancer led to the development
of gefitinib. Further, somatic mutations in EGFR
have also been found to be informative in predict-
ing sensitivity to gefitinib and in explaining inter-
ethnic variability in drug responses.390 Advances in
epigenetics have led to drug developments such as
inhibitors of DNA methylation (DNMTs); indeed,
5-azacytidine and 5-aza-20-deoxycytidine have
been approved in the treatment of AMLs and mye-
lodysplastic syndromes by the US FDA.391,392
These show that genomic discoveries can be
directly translated into clinical applications.
Given the advances in the field, more discoveries
will eventually translate into clinical applications and
management of patients. For example, GWASs have
led to several promising discoveries, such as the
identification of genetic variants in IL28B that
influence the spontaneous clearance of hepatitis C
virus and affect the individual response to chronic
hepatitis C of interferon-a plus ribavirin
therapy.393,394 Similarly, cancer genome sequencing
has identified promising somatic mutations in candi-
date genes (eg the isocitrate dehydrogenase 1 gene
[IDH1]) as potential targets for drug interventions.
Recurrent mutations in IDH1 have been found in
12 per cent of glioblastoma multiforme patients.318
The importance of this gene is not confined to glio-
blastoma multiforme, as mutations in IDH1 were
also found in 16 per cent of AML patients.325
In the era of GWASs and WGS, the great chal-
lenge lies in data interpretation and how genomic
information can be used to discover new drugs or
molecular biomarkers for clinical applications that
will eventually translate into patient benefit. The
ultimate goal of these studies is to improve the clini-
cal management of patients and to bring
about personalised medicine395,396 through the
development of new therapeutic agents tailored to
the individual, based upon their genetic information.
Although progress made towards achieving these
goals has been promising, many challenges in the
translational phase remain. Hence, it is still unclear
how long it will take for personalised genomic
medicine to become an everyday reality.
Summary
The analysis of the sequence of the human genome
has had a major impact on biomedical research
over the past few years. The HGP has made poss-
ible a multitude of genome-wide scale analyses and
has thus provided a wealth of information about
the architecture of the human genome. In many
ways, the HGP has paved the way for what is
coming to be called individualised or personalised
genome medicine. The development of new (gen-
otyping and sequencing) technologies for
improved, less cost-intensive and more precise
genome sequencing and assembly has been driven
by the overwhelming success of the HGP.
In summary, the advances discussed in this
review would not have been possible without the
reference genome sequence produced a decade ago
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by the HGP. These advances have greatly improved
our understanding of human genetic diversity,
disease genetics and functional genomics. The
development of powerful analytical and bioinfor-
matics tools is crucially important in the era of
genome sequencing (Box 9). The ongoing
large-scale international projects will further
contribute to the fields of human genetics, as well
as human genomics, transcriptomics, epigenomics
and metagenomics upon their completion. These
projects will provide vital resources for future
studies. Continued progress over the next ten years
will bring us closer to the final goal of personalised
genomic medicine.
Box 9. Bioinformatics — computational and analytical tools — in the
NGS era
Bioinformatics — and computational and analytical tools — play a key role in the NGS era, an era in
which huge amounts of sequencing data are being generated. Parallel developments in bioinformatics
tools have contributed greatly to recent advances in the field of human structural and functional geno-
mics where NGS technologies have been applied. A detailed discussion of the development of these
analytical tools and methodological pipelines is beyond the scope of this paper. However, bioinfor-
matics, computational and analytical tools have been developed for a variety of applications at different
stages of the analysis of data generated by both structural and functional genomics studies. Exemplars
are given below.
Base calling, alignment, mapping and assembly
1. Base-calling for NGS platforms.397
2. Survey of sequence alignment algorithms for NGS.398
3. Evaluation of NGS software in mapping and assembly.399
4. De novo assembly of short sequence reads.291
5. Assembly algorithms for NGS data.400
Structural genomics (discovery of genetic variations)
6. Computational methods for discovering structural variation with NGS.282
7. Combinatorial algorithms for structural variation detection in high-throughput sequenced
genomes.401
8. A framework for variation discovery and genotyping using NGS DNA data.402
Functional genomics
9. Introduction to the analysis of high-throughput-sequencing based epigenome data.403
10. Computation for ChIP-seq and RNA-seq studies.404
11. Bioinformatics approaches for genomics and post-genomics applications of NGS.405
Association studies
12. Association studies for NGS.406
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1 247,249,719 2,189 8.85 Largest human chromosome. Rich in disease genes. Huge (30 Mb)
pericentromeric heterochromatic region at 1q12 spans 5% of the
length of the chromosome. Contains clusters of amylase genes (1p21),
U1 snRNA genes (1q12-q22) and 5S RNA genes (1q) as well as multiple
(250) tRNA genes
1
2 242,951,149 1,328 5.47 Chromosome 2 (along with chromosome 4) exhibits the lowest
recombination rate of all the autosomes. Contains at 2q13 an ancient
telomere–telomere fusion junction at the position where two ape
chromosomes once fused to give rise to this human chromosome
2
3 199,501,827 1,112 5.57 Lowest rate of segmental duplication of all human chromosomes.
Contains several olfactory receptor gene clusters
3
4 191,273,063 797 4.17 Chromosome 4 (along with chromosome 2) exhibits the lowest
recombination rate of all the autosomes. Highest percentage of LINE
elements among all chromosomes
2
5 180,857,866 903 4.99 Rich in intra-chromosomal duplications. Contains interleukin and
protocadherin gene clusters on 5q31
4
6 170,899,992 1,133 6.62 Harbours the major histocompatibility complex and the largest tRNA
gene cluster in the human genome. Contains at least three imprinted
genes
5
7 158,821,424 1,023 6.44 Contains the highest number of intra-chromosomal duplications among
all human chromosomes. Contains at least six imprinted genes
6, 7
8 146,274,826 747 5.11 Contains a fast-evolving 15 Mb region on distal 8p with genes related to
the innate immunity and nervous systems that appear to have evolved
under positive selection
8
9 140,273,252 929 6.62 Structurally highly polymorphic. Contains the large (14 Mb) block of
pericentromeric heterochromatin. Contains large numbers of intra- and
inter-chromosomal segmental duplications, as well as the largest
interferon gene cluster in the human genome (9p22)
9





















































































































11 134,452,384 1,385 10.30 Rich in both genes and disease genes. Contains 40% of all olfactory
receptor gene clusters. Contains at least nine imprinted genes
11
12 132,349,534 1,080 8.16 Chromosome 12 has a unique history of evolutionary rearrangements
that occurred in the rodent and primate lineages. Contains clusters of
proline-rich protein and type II keratin genes at 12q13
12
13 114,142,980 361 3.16 Low gene density in general; contains a central 38 Mb segment where
the gene density drops to only 3.1 genes per Mb. This acrocentric
chromosome contains ribosomal RNA genes at 13p12 and at least
one imprinted gene
13
14 106,368,585 669 6.29 This acrocentric chromosome contains ribosomal RNA genes at 14p12.
Contains two 1 Mb regions of crucial importance to the immune
system (T cell receptor and immunoglobulin heavy chain genes).
Contains serpin gene cluster at 14q32.1 and several regions with
imprinted genes
14
15 100,338,915 641 6.39 This acrocentric chromosome contains ribosomal RNA genes at 15p12.
Two large clusters of clinically important segmental duplications are
located in the proximal and distal regions of 15q. Contains a number
of imprinted genes
15
16 88,827,254 925 10.41 Relatively high gene density. Contains a large number of segmental
duplications
16
17 78,774,742 1,236 15.69 High gene density. Has undergone extensive intra-chromosomal
rearrangement, many of which were probably mediated by segmental
duplications. High G þ C content of 45% (genome average: 41%)
17



































































































19 63,811,651 1,443 22.61 Highest gene density of all human chromosomes. One quarter of the
genes on chromosome 19 belong to tandemly arranged gene families,
encompassing 25% of the length of the chromosome. High G þ C
content of 48–49% (genome average: 41%). Repetitive sequences
constitute 53–57% of the chromosome, as compared with a genome
average of 40–44%. Contains clusters of olfactory receptor genes and
cytochrome P450 genes, and multiple clusters of zinc finger genes, and
at least two imprinted genes
19
20 62,435,964 617 9.88 Smallest metacentric autosome. Rich in both genes and disease genes.
Contains type 2 cystatin gene cluster and at least two imprinted genes
20
21 46,944,323 284 6.05 Smallest human chromosome with fewer genes than any other
autosome. This acrocentric chromosome contains ribosomal RNA
genes at 21p12
21
22 49,691,432 519 10.44 This acrocentric chromosome contains ribosomal RNA genes at 22p12.
Relatively high gene density. Clusters of segmental duplications at
22q11.2 are associated with several genomic disorders
22
X 154,913,754 891 5.75 Contains the pseudoautosomal regions, PAR1 and PAR2, at the tips of
the short and long arms, respectively. These regions are essential for
normal male meiosis and recombination. PAR1 undergoes an obligate
crossover with the Y chromosome, thereby giving this region the
highest recombination rate in the human genome, at least in males. One
X chromosome is subject to inactivation in females. Highly enriched in























































































































Y 57,772,954 80 1.38 Lowest gene density of all human chromosomes (contains only 82
known genes). Contains the male-specific region which is a mosaic of
heterochromatin and euchromatic X-transposed, X-degenerate and
ampliconic sequences that make up 30% of the euchromatin. PAR1
undergoes an obligate crossover with the X chromosome. The virtual
absence of homologous recombination between the X and the Y
chromosomes has led to a gradual degeneration of Y chromosomal
genes over evolutionary time. However, the absence of recombination,
at least within the extensive non-recombining region of the Y
chromosome, has also favoured the evolutionary accumulation of
transposable elements on the Y chromosome
24
aChromosome lengths and the numbers of genes per chromosome are according to the Ensembl database, version 47.36. The chromosome length corresponds to the length of each chromosome that has been sequenced so
far. The number of known protein-coding genes represents a conservative estimate of the likely total number, comprising genes which have been fully annotated. An earlier version of this table was published by
Kehrer-Sawatzki and Cooper.25
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